var title_f17_16_17664="Penile chancre in syphilis";
var content_f17_16_17664=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75291&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75291&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Primary syphilis: Penile chancre",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 203px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A chancre due to syphilis is an ulcerative lesion that is often painless and has an indurated character. Chancres arise at the site of initial inoculation of the organism.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles B Hicks, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_16_17664=[""].join("\n");
var outline_f17_16_17664=null;
var title_f17_16_17665="Pathophysiology MR in HCM";
var content_f17_16_17665=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54090&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54090&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mechanism of mitral regurgitation in hypertrophic cardiomyopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Differences in leaflet length and mobility influence the extent of mitral regurgitation. Panel A: The anterior and posterior mitral valve leaflets visibly coapt over a longer distance (contact length, C), resulting in a small amount of mitral regurgitation. Panel B: The posterior leaflet is limited in its ability to move anteriorly and the mitral leaftlets fail to coapt, resulting in a visible gap (G) and a greater degree of mitral regurgitation. The ability to coapt is determined both by the length of the posterior leaflet and by the range of motion permitted by its chordal and papillary muscle connections.",
"    <div class=\"footnotes\">",
"     &alpha;: angle between posterior left ventricular wall and basal part of posterior mitral leaflet; &beta;: angle between basal and apical (more distal) parts of posterior mitral leaflet.",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from Schwammenthal, E, Nakatani, S, He, S, et al, Circulation 1998; 98:856.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_16_17665=[""].join("\n");
var outline_f17_16_17665=null;
var title_f17_16_17666="Peutz-Jeghers syndrome lip pigmentation";
var content_f17_16_17666=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F55335&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F55335&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Peutz-Jeghers syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple pigmented macules are present on the lips.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_16_17666=[""].join("\n");
var outline_f17_16_17666=null;
var title_f17_16_17667="Chigger bites C";
var content_f17_16_17667=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F77496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F77496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chigger bites",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 453px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Skin lesions on a patient who sustained over 1000 chigger bites. Note the erythematous papules clustered along the waistline, a common location for chigger bites.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of JF Butler, Professor Emeritus, University of Florida.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_16_17667=[""].join("\n");
var outline_f17_16_17667=null;
var title_f17_16_17668="Magnesium salicylate: Patient drug information";
var content_f17_16_17668=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Magnesium salicylate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/37/14932?source=see_link\">",
"     see \"Magnesium salicylate: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F191030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Doan's&reg; Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Keygesic [OTC];",
"     </li>",
"     <li>",
"      Momentum&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain, swelling, and fever.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702438",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to magnesium salicylate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark, tarry-black stool.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10825 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-4B2100FB5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_16_17668=[""].join("\n");
var outline_f17_16_17668=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191030\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017033\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017032\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017037\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017038\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017040\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017035\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017036\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017041\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017042\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/37/14932?source=related_link\">",
"      Magnesium salicylate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_16_17669="Irbesartan: Patient drug information";
var content_f17_16_17669=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Irbesartan: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/37/21079?source=see_link\">",
"     see \"Irbesartan: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/5/26710?source=see_link\">",
"     see \"Irbesartan: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F184320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Avapro&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F184321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Avapro&reg;;",
"     </li>",
"     <li>",
"      CO Irbesartan;",
"     </li>",
"     <li>",
"      PMS-Irbesartan;",
"     </li>",
"     <li>",
"      ratio-Irbesartan;",
"     </li>",
"     <li>",
"      Sandoz-Irbesartan;",
"     </li>",
"     <li>",
"      Teva-Irbesartan",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Use during pregnancy may cause birth defects or loss of the unborn baby. If you get pregnant or plan on getting pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691575",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to protect kidney function in diabetic patients who have protein loss.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to irbesartan or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703720",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a block in the kidneys' arteries.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3915366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes) and are taking aliskiren.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a salt substitute that has potassium, potassium-sparing diuretics, or potassium, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High potassium level. Signs include feeling weak, lightheaded, dizzy, feel like passing out, or have numbness or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698395",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Kidney function that gets worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699070",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of high potassium.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have too much sweat, fluid loss, throwing up, or loose stools. This may lead to low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10771 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-FA3CAE7412-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_16_17669=[""].join("\n");
var outline_f17_16_17669=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184320\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184321\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019223\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019225\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019224\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019229\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019230\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019232\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019227\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019228\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019233\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019234\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/37/21079?source=related_link\">",
"      Irbesartan: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/5/26710?source=related_link\">",
"      Irbesartan: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_16_17670="WPW orthodromic AVRT";
var content_f17_16_17670=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Orthodromic atrioventricular reentrant tachycardia in WPW syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 386px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patient with Wolff-Parkinson-White (WPW) syndrome who had a concealed right free wall accessory pathway that only conducted retrogradely. The surface 12 lead ECG (bottom) shows a normal PR interval and QRS complex, without evidence of preexcitation. During the orthodromic atrioventricular reentrant tachycardia, the QRS complexes are narrow, identical to the QRS during sinus rhythm (bottom tracing).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_16_17670=[""].join("\n");
var outline_f17_16_17670=null;
var title_f17_16_17671="Evaluating response to treatment of chronic lymphocytic leukemia";
var content_f17_16_17671=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluating response to treatment of chronic lymphocytic leukemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/16/17671/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/16/17671/contributors\">",
"     Kanti R Rai, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/16/17671/contributors\">",
"     Michael J Keating, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/16/17671/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/16/17671/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/16/17671/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/16/17671/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/16/17671/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic lymphocytic leukemia (CLL) is one of the chronic lymphoproliferative disorders (lymphoid neoplasms) characterized by a progressive accumulation of a monoclonal population of functionally incompetent lymphocytes. CLL is considered to be identical (ie, one disease at different stages) to the mature (peripheral) B cell neoplasm small lymphocytic lymphoma (SLL) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17671/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The term CLL is used when the disease manifests primarily in the bone marrow and blood, while the term SLL is used when involvement is primarily nodal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=see_link\">",
"     \"Classification of the hematopoietic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment is indicated when there are disease-related symptoms or evidence of progression. Except for allogeneic hematopoietic cell transplantation (HCT), treatment options for CLL are not curative. The International Workshop Group on CLL (IWCLL) has published a revised version of the guidelines for evaluating disease response that were published in 1996 by the National Cancer Institute Working Group",
"    <span class=\"nowrap\">",
"     (NCI/WG)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17671/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. These efforts in developing standardized criteria for the evaluation of response have also allowed comparison of results from different therapeutic trials.",
"   </p>",
"   <p>",
"    The response evaluation and criteria will be reviewed here. The initial treatment of",
"    <span class=\"nowrap\">",
"     CLL/SLL,",
"    </span>",
"    the treatment of relapsed or refractory disease, and the management of the complications of CLL are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29352?source=see_link\">",
"     \"Overview of the treatment of chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30442?source=see_link\">",
"     \"Treatment of relapsed or refractory chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35017?source=see_link\">",
"     \"Overview of the complications of chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RESPONSE ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The specific evaluation performed to assess the response to therapy differs depending upon whether the patient is enrolled in a therapeutic research protocol or is being treated in clinical practice:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For those treated in clinical practice, evaluation of the response to treatment should always include a history, physical examination, and complete blood count with differential. The history should include questions regarding constitutional symptoms such as unintentional weight loss, fatigue, fevers, and night sweats. The physical examination should pay particular attention to the evaluation of lymphadenopathy, hepatomegaly, and splenomegaly.",
"      <br/>",
"      <br/>",
"      If the above clinical and hematologic parameters indicate a complete remission, the peripheral blood should be sent for immunophenotyping to evaluate for clonal lymphocytes. Bone marrow aspirate and biopsy is reserved for patients with cytopenias of uncertain cause.",
"     </li>",
"     <li>",
"      For those treated as a part of a research protocol, the evaluation includes all that was just discussed. In addition, abdominal involvement is evaluated using computed tomography (CT). Patients should also undergo bone marrow aspirate and biopsy at the time of complete remission. Assessment for minimal residual disease is often performed by four color flow cytometry. A lymph node biopsy should be obtained if transformation into an aggressive lymphoma is suspected (ie, Richter syndrome). (See",
"      <a class=\"local\" href=\"#H88972500\">",
"       'Minimal residual disease'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3609?source=see_link&amp;anchor=H4#H4\">",
"       \"Pathobiology and treatment of Richter's transformation in chronic lymphocytic leukemia/small lymphocytic lymphoma\", section on 'Clinical features'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3609?source=see_link&amp;anchor=H8#H8\">",
"       \"Pathobiology and treatment of Richter's transformation in chronic lymphocytic leukemia/small lymphocytic lymphoma\", section on 'Biopsy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The use of imaging studies is reserved for the research setting because it has not demonstrated a clinical benefit and is unlikely to change the management of most patients. This was demonstrated in a meta-analysis that included 1372 patients receiving initial therapy for CLL [",
"      <a class=\"abstract\" href=\"UTD.htm?17/16/17671/abstract/4\">",
"       4",
"      </a>",
"      ]. Of the 481 episodes of progressive disease, 77 percent were detected by clinical symptoms or changes in the blood counts. A decision to treat relapsed disease was made based upon the results of CT or ultrasound alone in only two patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RESPONSE CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Workshop Group on CLL (IWCLL) has published a revised version of the guidelines for evaluating disease response that were published in 1996 by the National Cancer Institute Working Group",
"    <span class=\"nowrap\">",
"     (NCI/WG)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17671/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. As with the initial assessment of response, the criteria vary slightly depending upon whether patients are enrolled in a therapeutic research protocol. Response is categorized as complete remission, partial remission, stable disease, or progressive disease. The additional category of clinical remission with minimal residual disease is used in the context of clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88972870\">",
"    <span class=\"h2\">",
"     For patients treated in clinical practice (not treated on protocol)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Complete remission",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients being treated in clinical practice (and who are not enrolled on a research protocol), a complete remission requires",
"    <strong>",
"     all",
"    </strong>",
"    of the following to be present at least two months after completion of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17671/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Absence of constitutional symptoms attributable to CLL. These include &ge;10 percent unintentional weight loss within the previous six months, fatigue that interferes with work or usual activities, fevers greater than 100.5&deg;F (&gt;38&deg;C) for &ge;2 weeks, or night sweats for &gt;1 month.",
"     </li>",
"     <li>",
"      No lymph nodes &gt;1.5 cm in diameter on physical examination",
"     </li>",
"     <li>",
"      No hepatomegaly or splenomegaly by physical examination",
"     </li>",
"     <li>",
"      Absolute neutrophil count",
"      <span class=\"nowrap\">",
"       &gt;1500/microL",
"      </span>",
"      [1.5 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L]",
"      </span>",
"     </li>",
"     <li>",
"      Platelet count",
"      <span class=\"nowrap\">",
"       &gt;100,000/microL",
"      </span>",
"      [100 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L]",
"      </span>",
"     </li>",
"     <li>",
"      Untransfused hemoglobin concentration &gt;11",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (110",
"      <span class=\"nowrap\">",
"       g/L)",
"      </span>",
"     </li>",
"     <li>",
"      No clonal lymphocytes in the peripheral blood by immunophenotyping",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h4\">",
"     Complete remission with incomplete bone marrow recovery",
"    </span>",
"    &nbsp;&mdash;&nbsp;A separate category is used for patients who fulfill all of the criteria for a complete remission yet have persistent neutropenia, anemia, or thrombocytopenia unrelated to their disease, but likely related to drug toxicity. These patients must have a normal bone marrow aspirate and biopsy with no evidence of clonal infiltrates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Partial remission",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general clinical practice, a partial remission (PR) is defined when at least one of the following criteria has been met along with one of the specific hematologic parameters described below. At least one of these criteria must be documented for a minimal duration of two months after the completion of therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A decrease in the peripheral absolute lymphocyte count by at least 50 percent from the level prior to therapy.",
"     </li>",
"     <li>",
"      A reduction in previously enlarged nodes by at least 50 percent with no increase in the size of any single lymph node and no new enlarged lymph nodes. For these purposes, the size of previously enlarged nodes is defined by the sum of the products of up to six lymph nodes. An increase of &lt;25 percent in a lymph node &lt;2 cm is not considered significant.",
"     </li>",
"     <li>",
"      If enlarged prior to therapy, the liver and spleen should be reduced in size by at least 50 percent based upon palpation or ultrasound.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One of the following hematologic parameters must be met in addition to one of the above criteria in order to qualify for a PR:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Absolute neutrophil count",
"      <span class=\"nowrap\">",
"       &ge;1500/microL",
"      </span>",
"      [1.5 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L]",
"      </span>",
"      or greater than 50 percent improvement over baseline (if this value was abnormally low at baseline) without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"       granulocyte colony-stimulating factor",
"      </a>",
"      support.",
"     </li>",
"     <li>",
"      Platelet count",
"      <span class=\"nowrap\">",
"       &ge;100,000/microL",
"      </span>",
"      [100 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L]",
"      </span>",
"      or at least 50 percent improvement over baseline (if this value was abnormally low at baseline).",
"     </li>",
"     <li>",
"      Hemoglobin concentration &ge;11",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (110",
"      <span class=\"nowrap\">",
"       g/L)",
"      </span>",
"      or 50 percent improvement over baseline (if this value was abnormally low at baseline) without red blood cell transfusions or erythropoietin support.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Progressive disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive disease (PD) is defined by the presence of one or more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The appearance of a newly enlarged lymph node (&gt;1.5 cm), splenomegaly, or hepatomegaly.",
"     </li>",
"     <li>",
"      An increase of 50 percent or more in size of a previously involved site (eg, lymph nodes, spleen, or liver). Lymph node enlargement is measured by the sum of the product of diameters of up to six involved nodes. A lymph node that was 1 to 1.5 cm previously must increase by 50 percent or more to a size greater than 1.5 to 2 cm in the longest axis.",
"     </li>",
"     <li>",
"      An increase of 50 percent or more in the total circulating lymphocyte count with at least 5000 lymphocytes per microL.",
"     </li>",
"     <li>",
"      Development of neutropenia, anemia, or thrombocytopenia attributable to CLL. Cytopenias cannot be used to determine disease progression during active therapy since they may be due to administered cytotoxic agents. Cytopenias that occur at least three months after the completion of therapy and are accompanied by an infiltrate of clonal CLL cells on bone marrow biopsy can be used to define disease progression. Specific values that define progression include a decrease in hemoglobin level by more than 2",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (20",
"      <span class=\"nowrap\">",
"       g/L)",
"      </span>",
"      or to less than 10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (100",
"      <span class=\"nowrap\">",
"       g/L)",
"      </span>",
"      or a decrease in platelet count by more than 50 percent or to less than",
"      <span class=\"nowrap\">",
"       100,000/microL",
"      </span>",
"      [100 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L].",
"      </span>",
"     </li>",
"     <li>",
"      Richter's transformation (the development of an aggressive large-cell lymphoma) as documented by lymph node biopsy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3609?source=see_link&amp;anchor=H8#H8\">",
"       \"Pathobiology and treatment of Richter's transformation in chronic lymphocytic leukemia/small lymphocytic lymphoma\", section on 'Biopsy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Stable disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who do not meet the criteria for a complete remission, partial remission, or progressive disease, have stable disease. Stable disease is therapeutically equivalent to a nonresponse (ie, refractory disease). (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Refractory disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88972882\">",
"    <span class=\"h2\">",
"     For patients on clinical trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following sections describe guidelines for evaluating disease response for patients enrolled on a research protocol published by the International Workshop Group on CLL (IWCLL) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17671/abstract/3\">",
"     3",
"    </a>",
"    ]. These guidelines rely upon surrogate markers of tumor burden (eg, blood lymphocyte count, lymph node size, spleen size) that have predicted clinical benefit in patients treated with traditional chemotherapy agents. Since their publication, it has been recognized that these surrogate markers may not accurately predict clinical benefit in patients treated with newer agents. This realization initiated a Lymphoma Research Foundation-sponsored workshop in May 2011, which culminated in the publication of recommended changes to the response criteria in patients treated with novel agents [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17671/abstract/5\">",
"     5",
"    </a>",
"    ]. These recommendations have been explicitly incorporated below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88972486\">",
"    <span class=\"h3\">",
"     Complete remission",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients enrolled on a research protocol, a complete remission (CR) requires",
"    <strong>",
"     all",
"    </strong>",
"    of the following to be present at least two months after completion of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17671/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Absence of constitutional symptoms attributable to CLL (ie, &ge;10 percent unintentional weight loss within the previous six months, fatigue that interferes with work or usual activities, fevers greater than 100.5&deg;F (&gt;38&deg;C) for &ge;2 weeks, or night sweats for &gt;1 month).",
"     </li>",
"     <li>",
"      No lymph nodes &gt;1.5 cm in diameter on computed tomography",
"     </li>",
"     <li>",
"      No hepatomegaly or splenomegaly by computed tomography",
"     </li>",
"     <li>",
"      Absolute neutrophil count",
"      <span class=\"nowrap\">",
"       &gt;1500/microL",
"      </span>",
"      [1.5 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L]",
"      </span>",
"     </li>",
"     <li>",
"      Platelet count",
"      <span class=\"nowrap\">",
"       &gt;100,000/microL",
"      </span>",
"      [100 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L].",
"      </span>",
"     </li>",
"     <li>",
"      Untransfused hemoglobin concentration &gt;11",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (110",
"      <span class=\"nowrap\">",
"       g/L)",
"      </span>",
"     </li>",
"     <li>",
"      No clonal lymphocytes in the peripheral blood by immunophenotyping",
"     </li>",
"     <li>",
"      A unilateral bone marrow aspirate and biopsy performed at least two months after the completion of therapy and before six months have elapsed is required to confirm the CR. If a hypocellular marrow is found, the bone marrow aspirate and biopsy should be repeated in four to six weeks provided the peripheral blood counts have recovered. The marrow should be free of clonal CLL cells by conventional flow cytometry",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      immunohistochemistry. If nodules (lymphoid aggregates) are found on bone marrow biopsy, these may represent residual disease (ie, nodular PR) and so should be assessed by immunohistochemistry to determine if they are principally comprised of CLL cells or of lymphocytes other than CLL cells or T cells. (See",
"      <a class=\"local\" href=\"#H88972514\">",
"       'Nodular partial remission'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88972493\">",
"    <span class=\"h4\">",
"     Complete remission with incomplete bone marrow recovery",
"    </span>",
"    &nbsp;&mdash;&nbsp;A separate category is used for patients who fulfill all of the criteria for a complete remission yet have persistent neutropenia, anemia, or thrombocytopenia unrelated to their disease, but likely related to drug toxicity. These patients must have a normal bone marrow aspirate and biopsy with no evidence of clonal infiltrates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88972500\">",
"    <span class=\"h4\">",
"     Minimal residual disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory tests based on multicolor flow cytometry and real time quantitative polymerase chain reaction (PCR) have demonstrated that most patients who achieve a complete remission following chemotherapy still have a detectable malignant clone [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17671/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. These studies can reliably detect approximately one CLL cell per 10,000 leukocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17671/abstract/3\">",
"     3",
"    </a>",
"    ]. As such, patients in some clinical trials are being evaluated for minimal residual disease (MRD). Those with less than one CLL cell per 10,000 leukocytes are considered in complete remission without MRD. At this time, studies for MRD are only recommended for patients enrolled in clinical trials.",
"   </p>",
"   <p>",
"    Initial results suggest that patients who have high levels of detectable MRD have inferior clinical outcomes when compared with those with low levels of MRD or without MRD. As an example, an analysis of the German CLL Study Group CLL8 trial reported that higher MRD levels were associated with shorter progression-free and overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17671/abstract/9\">",
"     9",
"    </a>",
"    ]. However, this analysis included not only patients in clinical CR, but also those with obvious residual CLL by cytology. Prospective trials are necessary to determine whether additional therapy to convert a response from a complete remission to a clinical remission with MRD is of significant clinical benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88972507\">",
"    <span class=\"h3\">",
"     Partial remission",
"    </span>",
"    &nbsp;&mdash;&nbsp;A partial remission (PR) is defined when at least one of the following general criteria has been met along with one of the specific hematologic parameters described below. At least one of these criteria must be documented for a minimal duration of two months after the completion of therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A decrease in the peripheral absolute lymphocyte count by at least 50 percent from the level prior to therapy.",
"     </li>",
"     <li>",
"      A reduction in previously enlarged nodes by at least 50 percent with no increase in the size of any single lymph node and no new enlarged lymph nodes. For these purposes, the size of previously enlarged nodes is defined by the sum of the products of up to six lymph nodes. An increase of &lt;25 percent in a lymph node &lt;2 cm is not considered significant.",
"     </li>",
"     <li>",
"      If enlarged prior to therapy, the liver and spleen should be reduced in size by at least 50 percent based upon computed tomography.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One of the following hematologic parameters must be met in addition to one of the above criteria in order to qualify for a PR:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Absolute neutrophil count",
"      <span class=\"nowrap\">",
"       &ge;1500/microL",
"      </span>",
"      [1.5 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L]",
"      </span>",
"      or greater than 50 percent improvement over baseline (if this value was abnormally low at baseline) without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"       granulocyte colony-stimulating factor",
"      </a>",
"      support.",
"     </li>",
"     <li>",
"      Platelet count",
"      <span class=\"nowrap\">",
"       &ge;100,000/microL",
"      </span>",
"      [100 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L]",
"      </span>",
"      or at least 50 percent improvement over baseline (if this value was abnormally low at baseline).",
"     </li>",
"     <li>",
"      Hemoglobin concentration &ge;11",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (110",
"      <span class=\"nowrap\">",
"       g/L)",
"      </span>",
"      or 50 percent improvement over baseline (if this value was abnormally low at baseline) without red blood cell transfusions or erythropoietin support.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88972514\">",
"    <span class=\"h4\">",
"     Nodular partial remission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent bone marrow nodules on bone marrow biopsy in patients achieving a CR or PR are classified separately as a nodular PR (PR-Nod). Lymphoid aggregates should be evaluated with immunohistochemistry to determine whether they are comprised of CLL cells, lymphocytes other than CLL cells, or T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17671/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35431?source=see_link&amp;anchor=H4#H4\">",
"     \"Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia\", section on 'Immunophenotype'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16073330\">",
"    <span class=\"h4\">",
"     Nodal response",
"    </span>",
"    &nbsp;&mdash;&nbsp;A nodal response has been used to describe a reduction in lymphadenopathy in the setting of persistent lymphocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17671/abstract/5\">",
"     5",
"    </a>",
"    ]. The term nodal response was initially designated for use in trials of B cell receptor and adhesion-related kinase inhibitors. Treatment with these agents commonly results in tumor mobilization from tissues into the peripheral blood characterized by the rapid development of lymphocytosis, often with a concomitant shrinkage of involved lymph nodes. The lymphocytosis usually resolves with continued treatment, but may be persistent. Such patients would be classified as having progressive disease based upon the IWCLL response criteria, despite an apparent clinical benefit. As such, the term nodal response was created in an attempt to more faithfully predict outcome with newer agents under clinical investigation. For patients receiving a drug associated with tumor mobilization, investigators should reserve the label PD for cases that demonstrate other definitive signs of PD (eg, anemia, thrombocytopenia, lymphadenopathy, hepatosplenomegaly). Lymphocytosis alone should not interfere with the identification of a partial response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88972521\">",
"    <span class=\"h3\">",
"     Progressive disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive disease (PD) is defined by the presence of one or more of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17671/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The appearance of a newly enlarged lymph node (&gt;1.5 cm), splenomegaly, or hepatomegaly.",
"     </li>",
"     <li>",
"      An increase of 50 percent or more in size of a previously involved site (eg, lymph nodes, spleen, or liver). Lymph node enlargement is measured by the sum of the product of diameters of involved nodes. A lymph node that was 1 to 1.5 cm previously must increase by 50 percent or more to a size greater than 1.5 to 2 cm in the longest axis.",
"     </li>",
"     <li>",
"      An increase of 50 percent or more in the total circulating lymphocyte count with at least 5000 lymphocytes per microL (see caveats below).",
"     </li>",
"     <li>",
"      Richter's transformation (the development of an aggressive large-cell lymphoma) as documented by lymph node biopsy.",
"     </li>",
"     <li>",
"      Development of neutropenia, anemia, or thrombocytopenia attributable to CLL. Cytopenias cannot be used to determine disease progression during active therapy since they may be due to administered cytotoxic agents. Cytopenias that occur at least three months after the completion of therapy and are accompanied by an infiltrate of clonal CLL cells on bone marrow biopsy can be used to define disease progression. Specific values that define progression include a decrease in hemoglobin level by more than 2",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (20",
"      <span class=\"nowrap\">",
"       g/L)",
"      </span>",
"      or to less than 10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (100",
"      <span class=\"nowrap\">",
"       g/L)",
"      </span>",
"      or a decrease in platelet count by more than 50 percent or to less than",
"      <span class=\"nowrap\">",
"       100,000/microL",
"      </span>",
"      [100 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L].",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The definition of PD from the IWCLL described above relies upon surrogate markers of tumor burden (eg, blood lymphocyte count, lymph node size, spleen size) that have predicted clinical benefit in patients treated with traditional chemotherapy agents. Importantly, these surrogate markers may not accurately predict clinical benefit in patients treated with newer agents (eg, immunomodulatory drugs, B cell receptor targeted drugs) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17671/abstract/5\">",
"     5",
"    </a>",
"    ]. Conclusions from a Lymphoma Research Foundation-sponsored workshop highlight the need to consider the following caveats with regard to PD [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17671/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Tumor flare",
"      </strong>",
"      &mdash; Tumor flare is a reaction to drug treatment predominantly characterized by the rapid development of painful and swollen lymphadenopathy with or without fever, bone pain, rash, and lymphocytosis [",
"      <a class=\"abstract\" href=\"UTD.htm?17/16/17671/abstract/10\">",
"       10",
"      </a>",
"      ]. It is most commonly seen in patients with CLL treated with immunomodulatory drugs, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      . Symptoms may resolve after a drug holiday",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      be mitigated by pretreatment with other agents (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      ). For patients receiving an immunomodulatory drug, investigators should reserve the label PD for cases that demonstrate symptoms of PD not typical of tumor flare or that fail to resolve after the introduction of interventions known to mitigate tumor flare.",
"     </li>",
"     <li>",
"      <strong>",
"       Tumor mobilization",
"      </strong>",
"      &mdash; Tumor mobilization from tissues into the peripheral blood is characterized by the rapid development of lymphocytosis, often with a concomitant shrinkage of involved lymph nodes. It is most commonly seen in patients with CLL treated with B cell receptor and adhesion-related kinase inhibitors. The lymphocytosis usually resolves with continued treatment, but may be persistent. For patients receiving a drug associated with tumor mobilization, investigators should reserve the label PD for cases that demonstrate other definitive signs of PD (eg, anemia, thrombocytopenia, lymphadenopathy, hepatosplenomegaly). Lymphocytosis alone should not interfere with the identification of a partial response. (See",
"      <a class=\"local\" href=\"#H16073330\">",
"       'Nodal response'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These suggestions incorporate clinical trial experience using these novel agents into the evaluation of PD in an attempt to avoid underestimating the clinical benefit of these agents. If these agents are approved for general use, these caveats or similar caveats will need to be incorporated into the standard response criteria for patients treated in clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88972528\">",
"    <span class=\"h3\">",
"     Stable disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who do not meet the criteria for a complete remission, partial remission, or progressive disease, have stable disease. Stable disease is therapeutically equivalent to a nonresponse. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Refractory disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RELAPSED DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapsed disease occurs in patients who have previously achieved either a complete or partial remission by the above criteria but then develop progressive disease after a period of six months or more. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30442?source=see_link\">",
"     \"Treatment of relapsed or refractory chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     REFRACTORY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who fail to achieve either a partial or complete remission with therapy or those who develop disease progression within six months of therapy have refractory disease. These treatment failures include patients with stable disease, nonresponsive disease, progressive disease, or death from any cause. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30442?source=see_link\">",
"     \"Treatment of relapsed or refractory chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/10/6309?source=see_link\">",
"       \"Patient information: Chronic lymphocytic leukemia (CLL) in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For evaluating disease response, the International Workshop on CLL (IWCLL) has published a revised version of the guidelines initially proposed in 1996 by the National Cancer Institute Working Group",
"      <span class=\"nowrap\">",
"       (NCI/WG).",
"      </span>",
"      These efforts in developing standardized criteria for the evaluation of response allow comparison of results from different therapeutic trials. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The specific evaluation to determine the response to therapy varies depending upon whether the patient is enrolled in a clinical trial or is being treated off protocol. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Response assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Special consideration must be made for patients treated with novel agents, for which the surrogate markers of tumor burden (eg, blood lymphocyte count, lymph node size, spleen size) may not accurately predict clinical benefit. Assessments that incorporate clinical trial experience with these novel agents may help to avoid underestimating their clinical benefit. (See",
"      <a class=\"local\" href=\"#H16073330\">",
"       'Nodal response'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H88972521\">",
"       'Progressive disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Relapsed disease occurs in patients who have previously achieved either a complete or partial remission but then develop progressive disease after a period of six months or more. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30442?source=see_link\">",
"       \"Treatment of relapsed or refractory chronic lymphocytic leukemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who fail to achieve either a partial or complete remission with therapy or those that develop disease progression within six months of therapy have refractory disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30442?source=see_link\">",
"       \"Treatment of relapsed or refractory chronic lymphocytic leukemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17671/abstract/1\">",
"      Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87:4990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17671/abstract/2\">",
"      Chronic lymphocytic leukemia: recommendations for diagnosis, staging, and response criteria. International Workshop on Chronic Lymphocytic Leukemia. Ann Intern Med 1989; 110:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17671/abstract/3\">",
"      Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111:5446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17671/abstract/4\">",
"      Eichhorst BF, Fischer K, Fink AM, et al. Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis. Blood 2011; 117:1817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17671/abstract/5\">",
"      Cheson BD, Byrd JC, Rai KR, et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol 2012; 30:2820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17671/abstract/6\">",
"      Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995; 333:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17671/abstract/7\">",
"      Rawstron AC, Kennedy B, Evans PA, et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001; 98:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17671/abstract/8\">",
"      Maloum K, Sutton L, Baudet S, et al. Novel flow-cytometric analysis based on BCD5+ subpopulations for the evaluation of minimal residual disease in chronic lymphocytic leukaemia. Br J Haematol 2002; 119:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17671/abstract/9\">",
"      B&ouml;ttcher S, Ritgen M, Fischer K, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 2012; 30:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17671/abstract/10\">",
"      Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006; 24:5343.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4501 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-2972EEEA2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_16_17671=[""].join("\n");
var outline_f17_16_17671=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RESPONSE ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RESPONSE CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88972870\">",
"      For patients treated in clinical practice (not treated on protocol)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Complete remission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Complete remission with incomplete bone marrow recovery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Partial remission",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Progressive disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Stable disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88972882\">",
"      For patients on clinical trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H88972486\">",
"      - Complete remission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H88972493\">",
"      Complete remission with incomplete bone marrow recovery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H88972500\">",
"      Minimal residual disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H88972507\">",
"      - Partial remission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H88972514\">",
"      Nodular partial remission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16073330\">",
"      Nodal response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H88972521\">",
"      - Progressive disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H88972528\">",
"      - Stable disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RELAPSED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      REFRACTORY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=related_link\">",
"      Classification of the hematopoietic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35017?source=related_link\">",
"      Overview of the complications of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29352?source=related_link\">",
"      Overview of the treatment of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3609?source=related_link\">",
"      Pathobiology and treatment of Richter's transformation in chronic lymphocytic leukemia/small lymphocytic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35431?source=related_link\">",
"      Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/10/6309?source=related_link\">",
"      Patient information: Chronic lymphocytic leukemia (CLL) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30442?source=related_link\">",
"      Treatment of relapsed or refractory chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_16_17672="Clinical trials of HIV antiretroviral therapy: Protease inhibitors";
var content_f17_16_17672=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical trials of HIV antiretroviral therapy: Protease inhibitors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/16/17672/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/16/17672/contributors\">",
"     Paul E Sax, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/16/17672/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/16/17672/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/16/17672/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/16/17672/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/16/17672/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The widespread use of combination antiretroviral therapy using nucleoside reverse transcriptase inhibitors (NRTIs) and a protease inhibitor (PI) dramatically improved the prognosis for people living with HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17672/abstract/1\">",
"     1",
"    </a>",
"    ]. With the potent PIs",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    , clinical trials demonstrated survival advantages for use of these drugs compared with regimens that consisted only of NRTIs [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17672/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Since the FDA approval in 1995 of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    , many additional protease inhibitors have been developed with varying efficacy and adverse event profiles.",
"   </p>",
"   <p>",
"    This topic will review the major clinical trials comparing protease inhibitors currently in common use:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    , lopinavir,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/11/44217?source=see_link\">",
"     fosamprenavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    . As neither",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    nor full dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    are presently preferred options for therapy in any clinical setting, studies evaluating their efficacy, safety, and tolerability will not be reviewed further here.",
"   </p>",
"   <p>",
"    A discussion of the relative advantages and disadvantages of the different drugs and the clinical context where they may be best utilized is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/61/986?source=see_link\">",
"     \"Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Details about pharmacology, dosing and side effect profiles, as well as \"pharmacokinetic boosting\" with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=see_link\">",
"     \"HIV protease inhibitors\"",
"    </a>",
"    .) Clinical trial information regarding other classes of HIV drugs is addressed within their respective topics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiretroviral therapy (ART) generally consists of at least three active antiretroviral medications. In treatment-na&iuml;ve patients, this consists of two NRTIs (sometimes referred to as the \"backbone\") and a third drug, either a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor. The selection of specific antiretroviral regimens is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Abbreviations used",
"    </span>",
"    &nbsp;&mdash;&nbsp;The protease inhibitors reviewed here include seven agents. Abbreviations used are:",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     Atazanavir",
"    </a>",
"    &nbsp; &nbsp; &nbsp; &nbsp;ATV &nbsp; &nbsp; Reyataz",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     Darunavir",
"    </a>",
"    &nbsp; &nbsp; &nbsp; &nbsp; DRV &nbsp; &nbsp; Prezista",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/11/44217?source=see_link\">",
"     Fosamprenavir",
"    </a>",
"    &nbsp;FPV &nbsp; &nbsp; &nbsp;Lexiva",
"   </p>",
"   <p>",
"    Lopinavir &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;LPV &nbsp; &nbsp; Kaletra",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"     Nelfinavir",
"    </a>",
"    &nbsp; &nbsp; &nbsp; &nbsp; NFV &nbsp; &nbsp; Viracept",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3482?source=see_link\">",
"     Saquinavir",
"    </a>",
"    &nbsp; &nbsp; &nbsp; &nbsp;SQV &nbsp; &nbsp; Invirase",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19992?source=see_link\">",
"     Tipranavir",
"    </a>",
"    &nbsp; &nbsp; &nbsp; &nbsp;TPV &nbsp; &nbsp; Aptivus",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     Ritonavir",
"    </a>",
"    is currently exclusively used as a pharmacokinetic booster at a dose much lower than when originally used for treatment. Use of low-dose ritonavir in these boosted regimens is indicated with a small \"r\" (eg,",
"    <span class=\"nowrap\">",
"     \"lopinavir/r\").",
"    </span>",
"    Pharmacokinetic boosting is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=see_link\">",
"     \"HIV protease inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TREATMENT-NAIVE PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies of protease inhibitor-containing regimens have been performed in treatment-naive patients over the past decade. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/61/986?source=see_link\">",
"     \"Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Lopinavir versus nelfinavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized, double-blind, placebo-controlled trial compared",
"    <span class=\"nowrap\">",
"     LPV/r",
"    </span>",
"    (400",
"    <span class=\"nowrap\">",
"     mg/100mg)",
"    </span>",
"    twice daily with NFV 750 mg three times daily in 653 treatment-naive patients who also received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    (d4T) 40 mg twice daily and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    (3TC) 150 mg twice daily [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17672/abstract/4\">",
"     4",
"    </a>",
"    ]. The median HIV RNA level was approximately 5 logs and the median CD4 count was approximately 260",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"    The primary outcome was attainment of viral suppression to &lt;400",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    at 24 weeks and loss of efficacy by 48 weeks.",
"   </p>",
"   <p>",
"    At week 24, more patients in the",
"    <span class=\"nowrap\">",
"     LPV/r",
"    </span>",
"    arm achieved viral suppression to &lt;400",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    than the NFV arm (79 versus 71 percent). These virologic trends continued; the proportions of patients who obtained persistent benefit through 48 weeks were 84 versus 66 percent for",
"    <span class=\"nowrap\">",
"     LPV/r",
"    </span>",
"    and NFV, respectively. Improvements in CD4 cell counts were similar between both arms.",
"   </p>",
"   <p>",
"    Patients treated with",
"    <span class=\"nowrap\">",
"     LPV/r",
"    </span>",
"    had greater increases in triglyceride concentrations than those treated with NFV (125 versus 47",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    increase). Both drugs were generally well tolerated and discontinuation rates were less than 4 percent in both arms.",
"   </p>",
"   <p>",
"    There were also striking differences regarding the emergence of drug resistance in the event of virologic failure [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17672/abstract/5\">",
"     5",
"    </a>",
"    ]. Specifically, patients with detectable viremia during weeks 24 through 48 were more likely to have resistance mutations if they were taking NFV than",
"    <span class=\"nowrap\">",
"     LPV/r",
"    </span>",
"    (33 percent versus none) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17672/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=see_link\">",
"     \"Drug resistance testing in the clinical management of HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Overall, this study demonstrated that",
"    <span class=\"nowrap\">",
"     LPV/r",
"    </span>",
"    is a more potent agent than NFV and is associated with lower rates of drug resistance. This trial led to the recommendation of",
"    <span class=\"nowrap\">",
"     LPV/r",
"    </span>",
"    as a preferred agent for the initial therapy of HIV in various treatment guidelines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Fosamprenavir versus nelfinavir (SOLO study)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized open-label trial compared",
"    <span class=\"nowrap\">",
"     FPV/r",
"    </span>",
"    <span class=\"nowrap\">",
"     (1400/200",
"    </span>",
"    mg) once daily with NFV 1250 mg twice daily in 649 treatment-naive patients who also received ABC and 3TC twice daily [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17672/abstract/6\">",
"     6",
"    </a>",
"    ]. The median HIV RNA level was 4.8 log and the median CD4 count was 170",
"    <span class=\"nowrap\">",
"     cells/microL;",
"    </span>",
"    20 percent had CD4 cell counts &lt;50 cells.",
"   </p>",
"   <p>",
"    At 48 weeks of follow-up, similar proportions of patients in the",
"    <span class=\"nowrap\">",
"     FPV/r",
"    </span>",
"    and NFV arms achieved a viral load &lt;400",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    (69 and 68 percent). However, fewer patients treated with",
"    <span class=\"nowrap\">",
"     FPV/r",
"    </span>",
"    experienced virologic failure (7 versus 17 percent). Conversely, there were more non-virologic failures in the",
"    <span class=\"nowrap\">",
"     FPV/r",
"    </span>",
"    than the NFV arm (24 versus 15 percent). CD4 cell count improvements were similar in both groups.",
"   </p>",
"   <p>",
"    Both regimens were generally well tolerated. Forty-four patients withdrew from the study due to an adverse event (9 percent in the",
"    <span class=\"nowrap\">",
"     FPV/r",
"    </span>",
"    arm and 5 percent in the NFV arm). Diarrhea was more commonly seen in the NFV arm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Fosamprenavir versus lopinavir (KLEAN study)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an open-label, non-inferiority study (Kaletra versus Lexiva with Epivir and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     Abacavir",
"    </a>",
"    in ART-Naive patients or \"KLEAN\"), 878 antiretroviral therapy-naive patients were randomly assigned to receive either",
"    <span class=\"nowrap\">",
"     FPV/r",
"    </span>",
"    (700",
"    <span class=\"nowrap\">",
"     mg/100",
"    </span>",
"    mg) twice daily or",
"    <span class=\"nowrap\">",
"     LPV/r",
"    </span>",
"    (400",
"    <span class=\"nowrap\">",
"     mg/100",
"    </span>",
"    mg) twice daily, each with the coformulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/4/3141?source=see_link\">",
"     abacavir-lamivudine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17672/abstract/7\">",
"     7",
"    </a>",
"    ]. The median HIV RNA levels were approximately 5 log and the median CD4 cell counts were approximately 190",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"   </p>",
"   <p>",
"    At",
"    week 48, similar rates of viral suppression (&lt;400",
"    <span class=\"nowrap\">",
"     copies/mL)",
"    </span>",
"    were achieved in both the",
"    <span class=\"nowrap\">",
"     FPV/r",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     LPV/r",
"    </span>",
"    arms (73 versus 71 percent, respectively). Non-inferiority of",
"    <span class=\"nowrap\">",
"     FPV/r",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     LPV/r",
"    </span>",
"    was also demonstrated in the more stringent category of HIV RNA suppression to less than 50",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    (66 versus 65 percent).",
"   </p>",
"   <p>",
"    Treatment discontinuations and reported adverse events (such as diarrhea) occurred with similar frequencies in both arms. Comparable elevations in plasma lipids were seen with both regimens.",
"   </p>",
"   <p>",
"    While the results of this study clearly demonstrated the non-inferiority of twice-daily",
"    <span class=\"nowrap\">",
"     FPV/r",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     LPV/r",
"    </span>",
"    for initial therapy of HIV, an important caveat is that the older soft-gel formulation of",
"    <span class=\"nowrap\">",
"     LPV/r",
"    </span>",
"    was used, which is no longer available. The present tablet formulation has a lower pill burden, is more heat-stable, and can be taken with or without regard to food. This limitation in comparator studies with",
"    <span class=\"nowrap\">",
"     LPV/r",
"    </span>",
"    also applies to the CASTLE and ARTEMIS studies, discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Fosamprenavir versus atazanavir (ALERT trial)",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/11/44217?source=see_link\">",
"     Fosamprenavir",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    was compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    plus ritonavir in treatment-na&iuml;ve patients in the ALERT trial; all study subjects also received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17672/abstract/8\">",
"     8",
"    </a>",
"    ]. Importantly, the dosing of fosamprenavir once daily was different than the originally FDA-approved dose; here 1400 mg of fosamprenavir was given with 100 mg (not 200 mg) of ritonavir; the atazanavir and ritonavir dosing were the standard 300 mg and 100 mg daily, respectively. One hundred six patients were enrolled. At 48 weeks, 75 percent of the FPV-treated patients and 83 percent of the ATV-treated patients had a viral load &lt;50",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    (p = 0.34), and both regimens were well tolerated. While the results suggest that FPV and ATV have comparable efficacy in treatment-na&iuml;ve patients, the study was not powered to make this conclusion definitively.",
"   </p>",
"   <p>",
"    Based on these data and the pharmacokinetic profile of FPV when dosed with 100 mg (rather than 200 mg) of RTV, the FDA has subsequently approved this dosing strategy for FPV in treatment-na&iuml;ve patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Atazanavir versus lopinavir (CASTLE)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy and safety of once-daily",
"    <span class=\"nowrap\">",
"     ATV/r",
"    </span>",
"    compared to twice-daily",
"    <span class=\"nowrap\">",
"     LPV/r",
"    </span>",
"    (with the older soft gel formulation), each in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    <span class=\"nowrap\">",
"     (TDF/FTC),",
"    </span>",
"    was evaluated in a non-inferiority trial involving 883 treatment-naive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17672/abstract/9\">",
"     9",
"    </a>",
"    ]. The median CD4 cell count was 205",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    and the median HIV RNA was 4.98 log(10)",
"    <span class=\"nowrap\">",
"     copies/microL.",
"    </span>",
"    The primary endpoint was viral suppression to the stringent cut-off of &lt;50",
"    <span class=\"nowrap\">",
"     copies/mL.",
"    </span>",
"   </p>",
"   <p>",
"    At",
"    48 weeks, viral suppression rates (&lt;50",
"    <span class=\"nowrap\">",
"     copies/microL)",
"    </span>",
"    were similar in both arms (78 and 76 percent, respectively) and CD4 gains were also comparable (203 and 219",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    respectively). No differences between arms were seen when stratified by HIV RNA less than or greater than 100,000",
"    <span class=\"nowrap\">",
"     copies/mL,",
"    </span>",
"    or by CD4 cell count; however, in a post-hoc analysis, a trend towards lower response rates in the",
"    <span class=\"nowrap\">",
"     LPV/r",
"    </span>",
"    arm in those with lower CD4 cell counts was observed. Rates of viral suppression at the 96-week follow-up were higher in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    arm compared with the lopinavir arm (74 versus 68 percent), establishing non-inferiority of this regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17672/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A better lipid profile was observed in patients taking",
"    <span class=\"nowrap\">",
"     ATV/r",
"    </span>",
"    compared to those taking LPV. Gastrointestinal side effects were more common in the",
"    <span class=\"nowrap\">",
"     LPV/r",
"    </span>",
"    group, while those receiving",
"    <span class=\"nowrap\">",
"     ATV/r",
"    </span>",
"    were more likely to experience jaundice related to drug-induced hyperbilirubinemia. Both treatments, however, were very well tolerated overall.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Darunavir versus lopinavir (ARTEMIS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized, open-label, phase 3 non-inferiority trial (ARTEMIS) compared the safety and efficacy of",
"    <span class=\"nowrap\">",
"     DRV/r",
"    </span>",
"    <span class=\"nowrap\">",
"     (800/100",
"    </span>",
"    mg once daily) with",
"    <span class=\"nowrap\">",
"     LPV/r",
"    </span>",
"    in 689 treatment-naive patients who were stratified by baseline viral load [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17672/abstract/11\">",
"     11",
"    </a>",
"    ]. All patients were also receiving fixed-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    <span class=\"nowrap\">",
"     (TDF/FTC).",
"    </span>",
"    The patients who were randomly assigned to the",
"    <span class=\"nowrap\">",
"     LPV/r",
"    </span>",
"    arm were allowed to take this medication once or twice daily (assuming domestic approval for once-daily dosing at the study site). Although most patients in this arm were initially receiving the older soft-gel formulation of",
"    <span class=\"nowrap\">",
"     LPV/r,",
"    </span>",
"    by the end of the study 85 percent were taking the newer tablet formulation.",
"   </p>",
"   <p>",
"    At week 48,",
"    <span class=\"nowrap\">",
"     DRV/r",
"    </span>",
"    was found to be non-inferior to",
"    <span class=\"nowrap\">",
"     LPV/r;",
"    </span>",
"    viral suppression was achieved in 84 versus 78 percent, respectively. In addition, among those patients with high baseline HIV RNA levels,",
"    <span class=\"nowrap\">",
"     DRV/r",
"    </span>",
"    achieved significantly higher virologic response rates than",
"    <span class=\"nowrap\">",
"     LPV/r",
"    </span>",
"    (79 versus 67 percent); the difference was particularly notable when comparing",
"    <span class=\"nowrap\">",
"     DRV/r",
"    </span>",
"    to once-daily",
"    <span class=\"nowrap\">",
"     LPV/r.",
"    </span>",
"   </p>",
"   <p>",
"    At 96 weeks, significantly more patients in the",
"    <span class=\"nowrap\">",
"     DRV/r",
"    </span>",
"    arm achieved viral suppression than in the",
"    <span class=\"nowrap\">",
"     LPV/r",
"    </span>",
"    arm (79 versus 71 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17672/abstract/12\">",
"     12",
"    </a>",
"    ]. The superiority of",
"    <span class=\"nowrap\">",
"     DRV/r",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     LPV/r",
"    </span>",
"    was also demonstrated in the subgroup of patients with a baseline viral load &gt;100,000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    (76 versus 63 percent) and in the subset of patients with a baseline CD4 cell count of &lt;200",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    (79 versus 65 percent).",
"   </p>",
"   <p>",
"    Both treatments were well tolerated. Compared with the",
"    <span class=\"nowrap\">",
"     LPV/r",
"    </span>",
"    arm, fewer patients in the",
"    <span class=\"nowrap\">",
"     DRV/r",
"    </span>",
"    arm had grade 2 to 4 treatment-related diarrhea (4 versus 11 percent) and fewer discontinued treatment due to adverse events (4 versus 9 percent). Rash occurred infrequently with administration of either medication (3 percent in the",
"    <span class=\"nowrap\">",
"     DRV/r",
"    </span>",
"    arm versus 1 percent in the",
"    <span class=\"nowrap\">",
"     LPV/r",
"    </span>",
"    arm).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Saquinavir versus lopinavir (GEMINI study)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Gemini Study was a prospective phase IIIb, randomized, open-label 48-week non-inferiority trial comparing",
"    <span class=\"nowrap\">",
"     SQV/r",
"    </span>",
"    twice daily versus",
"    <span class=\"nowrap\">",
"     LPV/r",
"    </span>",
"    twice daily, each taken in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    <span class=\"nowrap\">",
"     (FTC/TDF)",
"    </span>",
"    once daily [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17672/abstract/13\">",
"     13",
"    </a>",
"    ]. The primary efficacy endpoint was the proportion of patients with an HIV-1 RNA viral load &lt;50",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    at week 48. The median HIV RNA level was 5.2 log (10)",
"    <span class=\"nowrap\">",
"     copies/mL;",
"    </span>",
"    the median CD4 count was 137 cells.",
"   </p>",
"   <p>",
"    The final 48-week results suggested similar rates of viral suppression between the two arms (64 versus 65 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17672/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition, CD4 cell count gains were similar in the",
"    <span class=\"nowrap\">",
"     SQV/r",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     LPV/r",
"    </span>",
"    arms (178 versus 204 cells).",
"   </p>",
"   <p>",
"    After 48 weeks of therapy, changes in triglyceride and cholesterol levels demonstrated mixed results; triglyceride levels were higher in the",
"    <span class=\"nowrap\">",
"     LPV/r",
"    </span>",
"    arm whereas LDL levels were higher in the",
"    <span class=\"nowrap\">",
"     SQV/r",
"    </span>",
"    arm. In aggregate, the results of GEMINI do not demonstrate any advantages of",
"    <span class=\"nowrap\">",
"     SQV/r",
"    </span>",
"    over",
"    <span class=\"nowrap\">",
"     LPV/r;",
"    </span>",
"    indeed,",
"    <span class=\"nowrap\">",
"     LPV/r",
"    </span>",
"    currently has a lower pill burden and the advantage of heat-stable coformulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Summary of selection of PIs in the treatment-naive patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of the above studies generally demonstrate excellent overall virologic response rates with all of the boosted PIs, with differences seen mainly in the adverse event profile. Recent studies suggest that boosted PI regimens containing 100 mg rather than 200 mg of daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    generally have a lower rate of gastrointestinal side effects and hyperlipidemia. Importantly, all the studies show a relatively low rate of PI resistance mutations in the event of virologic failure. This property of boosted-PI regimens distinguish them from NNRTI-based initial treatments, which more commonly have resistance to one or two-drug classes when virologic failure occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17672/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT-EXPERIENCED PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several clinical trials have compared different boosted PIs in treatment-experienced patients. Over time, there has been an increased appreciation for the importance of including at least two (and preferably three) active drugs, as measured by resistance testing and the use (if available) of new drug classes. As a general rule, the higher the number of baseline mutations, the lower the likelihood of a virologic response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34218?source=see_link\">",
"     \"Primer on interpretation of HIV drug resistance testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Atazanavir/r versus atazanavir/saquinavir versus lopinavir/r",
"    </span>",
"    &nbsp;&mdash;&nbsp;An open-label randomized trial compared",
"    <span class=\"nowrap\">",
"     ATV/r",
"    </span>",
"    (300",
"    <span class=\"nowrap\">",
"     mg/100",
"    </span>",
"    mg) daily, ATV (400 mg) daily plus SQV (1200 mg daily), and",
"    <span class=\"nowrap\">",
"     LPV/r",
"    </span>",
"    (400",
"    <span class=\"nowrap\">",
"     mg/100",
"    </span>",
"    mg) twice daily in 358 patients who had failed at least two prior ART regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17672/abstract/16\">",
"     16",
"    </a>",
"    ]. All patients were also treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    (TDF) 300 mg daily plus a nucleoside analog (chosen by phenotypic testing when available) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17672/abstract/16\">",
"     16",
"    </a>",
"    ]. This non-inferiority study used",
"    <span class=\"nowrap\">",
"     LPV/r",
"    </span>",
"    as the reference standard.",
"   </p>",
"   <p>",
"    After 48 weeks, the efficacy of",
"    <span class=\"nowrap\">",
"     ATV/r",
"    </span>",
"    was demonstrated to be non-inferior to",
"    <span class=\"nowrap\">",
"     LPV/r",
"    </span>",
"    while the efficacy of the",
"    <span class=\"nowrap\">",
"     ATV/SQV",
"    </span>",
"    arm was significantly lower. Viral load reductions were 1.93 log(10), 1.87 and 1.55 in the",
"    <span class=\"nowrap\">",
"     ATV/r,",
"    </span>",
"    <span class=\"nowrap\">",
"     LPV/r,",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     ATV/SQV",
"    </span>",
"    arms, respectively. Mean CD4 cell count increases were 110, 121, and 72 x 10(6)",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    for",
"    <span class=\"nowrap\">",
"     ATV/r,",
"    </span>",
"    <span class=\"nowrap\">",
"     LPV/r,",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     ATV/SQV,",
"    </span>",
"    respectively.",
"   </p>",
"   <p>",
"    Declines in total cholesterol and fasting triglycerides were significantly greater in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    -containing arms than with",
"    <span class=\"nowrap\">",
"     LPV/r.",
"    </span>",
"    Lipids in the",
"    <span class=\"nowrap\">",
"     LPV/r",
"    </span>",
"    arm at week 48 generally increased from baseline. Patients with higher degrees of baseline PI resistance in general had better virologic responses to",
"    <span class=\"nowrap\">",
"     LPV/r",
"    </span>",
"    than",
"    <span class=\"nowrap\">",
"     ATV/r.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Tipranavir versus optimized regimen (RESIST-1 and RESIST-2)",
"    </span>",
"    &nbsp;&mdash;&nbsp;RESIST-1 and RESIST-2 are similar open-label trials comparing",
"    <span class=\"nowrap\">",
"     TPV/r",
"    </span>",
"    (500",
"    <span class=\"nowrap\">",
"     mg/200",
"    </span>",
"    mg) twice daily with another boosted PI-based regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17672/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. RESIST-1 studied 630 patients who had previously received at least three classes of antiretroviral medications, including at least two PI-based ART regimens. Patients had at least one PI mutation and a viral load above 1000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    at baseline. Prior to randomization, an optimized regimen was constructed based on boosted LPV, SQV, amprenavir, or IDV. Patients were then randomly assigned to the optimized regimen or a TPV-based regimen. The main efficacy endpoint was a treatment response, defined as a &ge;1 log decline in HIV RNA at 24 weeks.",
"   </p>",
"   <p>",
"    At 24 weeks, greater viral load reductions were seen in the",
"    <span class=\"nowrap\">",
"     TPV/r",
"    </span>",
"    arm (-1.28 versus -0.64 log); also a greater percentage of patients receiving a TPV-based regimen achieved a viral load below 50",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    than in the optimized PI arm (25 versus 10 percent). Similar results were seen in RESIST-2, which included 863 patients. In both trials, laboratory abnormalities were more common in the TPV arms, including elevated aminotransferases and hyperlipemia.",
"   </p>",
"   <p>",
"    The ability to achieve viral suppression was directly related to the number of TPV resistance mutations at baseline. For example, the proportion of virologic responders was 70 percent in those patients who had only one or two of these amino acid substitutions at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17672/abstract/19\">",
"     19",
"    </a>",
"    ]. In contrast, the proportion of responders declined to only 41 percent in those patients with five or more of these baseline substitutions. In addition, the virologic response rate dropped from 45 to 21 percent if the baseline phenotype had a greater than threefold shift in the 50 percent effective drug concentration (EC50).",
"   </p>",
"   <p>",
"    These data suggest a role for both genotypic and phenotypic testing in assessing a potential response to TPV in patients with extensive treatment experience. However, given the complexity of the genotypic patterns in patients with high-level PI resistance, many clinicians prefer to use phenotypic testing to assess possible response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    in this setting. A full discussion of tipranavir-related drug mutations is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34218?source=see_link\">",
"     \"Primer on interpretation of HIV drug resistance testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=see_link\">",
"     \"Drug resistance testing in the clinical management of HIV infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/48/4873?source=see_link\">",
"     \"Overview of HIV drug resistance testing assays\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This trial also highlighted the potential role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"     enfuvirtide",
"    </a>",
"    (ENF) in achieving viral suppression. The addition of ENF improved the treatment response from 31 to 58 percent in the TPV arm and from 19 to 30 percent in the optimized PI arm. The effect of enfuvirtide was blunted by prior exposure to this drug with lower response rates in the treatment-experienced group (31 versus 67 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Darunavir versus optimized therapy (POWER trials)",
"    </span>",
"    &nbsp;&mdash;&nbsp;POWER 1 and POWER 2 were randomized, multinational, phase IIB trials, which compared DRV coadministered with low-dose RTV to other PIs in a population of highly treatment-experienced patients.",
"   </p>",
"   <p>",
"    POWER 1 compared the efficacy and safety of four doses of DRV (TMC114) plus 100 mg RTV with investigator-selected control protease inhibitors (CPIs) in 318 treatment-experienced patients over 24 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17672/abstract/20\">",
"     20",
"    </a>",
"    ]. The mean baseline viral load was 4.48 log(10)",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    and the median CD4 cell count was 179",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"    Overall, 63 percent of the patients were resistant to all commercially available protease inhibitors.",
"   </p>",
"   <p>",
"    Virologic and immunologic outcomes were significantly better in the",
"    <span class=\"nowrap\">",
"     DRV/r",
"    </span>",
"    arms compared to the CPI arm. In the 600 mg DRV twice daily arm, mean CD4 gains were as high as 124 cells at 24 weeks and 53 percent attained an HIV RNA level &lt;50",
"    <span class=\"nowrap\">",
"     copies/mL;",
"    </span>",
"    these results led to selection of this dosage for regulatory approval in treatment-experienced patients. Similar efficacy data emerged from the POWER 2 trial [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17672/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=see_link\">",
"     \"HIV protease inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted in the TPV study above, the ability to achieve viral suppression was related to the number of mutations at baseline. In a pooled subset analysis of POWER 1 and POWER 2, the effect of baseline susceptibility on treatment efficacy was examined [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17672/abstract/22\">",
"     22",
"    </a>",
"    ]. Forty-seven percent of patients treated with DRV, who had up to eight mutations at baseline, still attained viral suppression. In contrast, only 25 percent of patients who received a control PI with activity against the baseline isolate attained an HIV RNA &lt;50",
"    <span class=\"nowrap\">",
"     copies/mL.",
"    </span>",
"    Of note, at 24 weeks, more than 60 percent of ENF-naive patients who were treated with ENF, in addition to DRV, achieved undetectable HIV RNA levels [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17672/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a subsequent larger trial (POWER 3), 327 treatment-experienced patients were treated with",
"    <span class=\"nowrap\">",
"     DRV/r",
"    </span>",
"    plus optimized background therapy in an effort to further evaluate the efficacy of the drug in a larger population of patients with advanced disease and multidrug-resistant HIV (median CD4 count 115",
"    <span class=\"nowrap\">",
"     cells/microL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17672/abstract/24\">",
"     24",
"    </a>",
"    ]. No comparator arm was used. Of 324 patients who were treated for 48 weeks, 45 percent achieved HIV RNA reductions to &lt;50",
"    <span class=\"nowrap\">",
"     copies/mL.",
"    </span>",
"   </p>",
"   <p>",
"    These studies confirm both the potency of DRV in treatment-experienced patients with extensive baseline PI resistance; they also reinforce the importance of an additional fully active drug for maximizing virologic response, as again use of ENF significantly improved virologic suppression rates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Darunavir versus lopinavir (TITAN)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy and safety of",
"    <span class=\"nowrap\">",
"     DRV/r",
"    </span>",
"    was subsequently compared to",
"    <span class=\"nowrap\">",
"     LPV/r",
"    </span>",
"    at 48 weeks in treatment-experienced patients in a randomized controlled phase III non-inferiority trial (TITAN) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17672/abstract/25\">",
"     25",
"    </a>",
"    ]. To be eligible, patients had to have virologic failure and no prior exposure to",
"    <span class=\"nowrap\">",
"     LPV/r.",
"    </span>",
"    All patients received optimized background regimen according to baseline genotypic and phenotypic testing. Of 595 study participants, approximately one-third were PI-naive and 82 percent were susceptible to four or more protease inhibitors. As such, these were patients with much less baseline drug resistance than those in the POWER studies.",
"   </p>",
"   <p>",
"    At week 48, significantly more patients in the DRV arm had achieved a viral load &lt;400",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    compared to the LPV arm (77 versus 68 percent). The results favored",
"    <span class=\"nowrap\">",
"     DRV/r",
"    </span>",
"    in those with any degree of baseline PI resistance. Fewer patients treated with",
"    <span class=\"nowrap\">",
"     DRV/r",
"    </span>",
"    than with",
"    <span class=\"nowrap\">",
"     LPV/r",
"    </span>",
"    developed PI mutations (21 versus 36 percent) and fewer patients on",
"    <span class=\"nowrap\">",
"     DRV/r",
"    </span>",
"    developed nucleoside analog-associated mutations than those taking",
"    <span class=\"nowrap\">",
"     LPV/r",
"    </span>",
"    (14 versus 27 percent). Most DRV-treated patients with virologic failure retained susceptibility to other protease inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17672/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Side effects included excess rashes in the DRV group and more diarrhea in the lopinavir group. Grade three or four adverse events occurred with similar frequency in both arms.",
"   </p>",
"   <p>",
"    A small retrospective analysis of the POWER 1 and 2 trials determined that in patients with no baseline DRV-associated mutations (n = 52 patients), the",
"    <span class=\"nowrap\">",
"     800/100",
"    </span>",
"    mg once-daily dose was as effective as the",
"    <span class=\"nowrap\">",
"     600/100",
"    </span>",
"    mg twice-daily dose [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17672/abstract/27\">",
"     27",
"    </a>",
"    ]. A prospective study will further evaluate the safety and efficacy of this dose in treatment-experienced patients without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Since 1995, multiple protease inhibitors have been developed with varying efficacy and different side effect profiles. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Full dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"       indinavir",
"      </a>",
"      are rarely used today, having been replaced by better-tolerated agents. Low dose ritonavir is used as a pharmacokinetic booster of other protease inhibitors (PIs). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Treatment-naive patients",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Comparative studies show that boosted PIs have lower rates of virologic failure and development of resistance mutations than unboosted PIs and are thus the generally preferred therapy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Treatment-naive patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20378?source=see_link\">",
"       Lopinavir-ritonavir",
"      </a>",
"      was demonstrated to have superior immunologic and virologic efficacy compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"       nelfinavir",
"      </a>",
"      in treatment-na&iuml;ve patients. Subsequent studies comparing other boosted PIs (eg,",
"      <span class=\"nowrap\">",
"       FPV/r,",
"      </span>",
"      <span class=\"nowrap\">",
"       ATV/r,",
"      </span>",
"      <span class=\"nowrap\">",
"       DRV/r,",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       SQV/r)",
"      </span>",
"      to",
"      <span class=\"nowrap\">",
"       LPV/r",
"      </span>",
"      have demonstrated that these agents are non-inferior in virologic efficacy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Treatment-naive patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ART regimens utilizing 100",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      for pharmacokinetic boosting generally have more favorable gastrointestinal and lipid side effect profiles compared with higher doses (eg, 200",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Treatment-naive patients'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Treatment-experienced patients",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For treatment-experienced patients, the choice of PI should be dictated by resistance testing. As a general rule, the higher the number of baseline mutations, the lower the likelihood of a virologic response. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment-experienced patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with no baseline PI resistance, the selection of a boosted PI should be based on similar considerations as when selecting a boosted PI in treatment-na&iuml;ve patients. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment-experienced patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who do have PI resistance, the TITAN study demonstrated that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"       darunavir",
"      </a>",
"      -",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      was superior to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20378?source=see_link\">",
"       lopinavir-ritonavir",
"      </a>",
"      in virologic efficacy. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment-experienced patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, when a large number of PI mutations are present, either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"       darunavir",
"      </a>",
"      -",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19992?source=see_link\">",
"       tipranavir",
"      </a>",
"      -ritonavir should be included in the treatment regimen; the ultimate drug selection should be based on results of phenotype resistance testing. Compared with tipranavir, darunavir has a more favorable side effect profile, fewer drug-drug interactions, and lower pill burden than tipranavir. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment-experienced patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In order to maximize treatment responses, inclusion of at least one and preferably two other fully active agents from previously unused drug classes is recommended. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment-experienced patients'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17672/abstract/1\">",
"      Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17672/abstract/2\">",
"      Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 1998; 351:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17672/abstract/3\">",
"      Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17672/abstract/4\">",
"      Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346:2039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17672/abstract/5\">",
"      Kempf DJ, King MS, Bernstein B, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004; 189:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17672/abstract/6\">",
"      Gathe JC Jr, Ive P, Wood R, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS 2004; 18:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17672/abstract/7\">",
"      Eron J Jr, Yeni P, Gathe J Jr, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 2006; 368:476.",
"     </a>",
"    </li>",
"    <li>",
"     Smith K, Weinberg W, DeJesus E, et al. Once-daily ritonavir (100 mg) boosting of fosamprenavir (FPV/r) or atazanavir (ATZ/r) with tenofovir (TDF)/emtricitabine (FTC) in antiretroviral-na&iuml;ve HIV-infected patients: 48-week safet/efficacy results from COL103952 (ALERT) [Abstract WEPEB023]. Fourth IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17672/abstract/9\">",
"      Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17672/abstract/10\">",
"      Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010; 53:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17672/abstract/11\">",
"      Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008; 22:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17672/abstract/12\">",
"      Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 2009; 23:1679.",
"     </a>",
"    </li>",
"    <li>",
"     Raffi F, Ward D, Ruxrungtham K, et al. Saquinavir/ritonavir BID vs lopinavir/ritonavir BID plus emtricitabine/tenofovir QD as initial therapy in HIV-1-infected patients: the Gemini Study 24-week interim analysis. Presented at the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia abstract # WePeB027.",
"    </li>",
"    <li>",
"     Walmsley S, Ruxrungham K, Slim J, et al. Saquinavir (QV/r) BID versus lopinavir (LPV/r) TWICE DAILY, plus emtricitabine/tenofovir (FTC/TDF) qD as initial therapy in HIV-infected patients; the GEMINI study (Abstract PS/4). 11th European AIDS Conference, Madrid, 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17672/abstract/15\">",
"      Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358:2095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17672/abstract/16\">",
"      Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005; 19:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17672/abstract/17\">",
"      Gathe J, Cooper DA, Farthing C, et al. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial. Clin Infect Dis 2006; 43:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17672/abstract/18\">",
"      Cahn P, Villacian J, Lazzarin A, et al. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin Infect Dis 2006; 43:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17672/abstract/19\">",
"      Naeger LK, Struble KA. Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients. AIDS 2007; 21:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17672/abstract/20\">",
"      Katlama C, Esposito R, Gatell JM, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007; 21:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17672/abstract/21\">",
"      Haubrich R, Berger D, Chiliade P, et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS 2007; 21:F11.",
"     </a>",
"    </li>",
"    <li>",
"     De Meyer S, Hill A, De Baere I, et al. Effect of baseline susceptibility and on-treatment mutations of TMC114 and control PI efficacy: preliminary analysis of data from PI-experienced patients form POWER 1 and POWER 2. Presented at the 13th annual Conference on Retroviruses and Opportunistic Infections, Denver, CO, February 5-8th, 2006; abstract #157.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17672/abstract/23\">",
"      Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17672/abstract/24\">",
"      Molina JM, Cohen C, Katlama C, et al. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3. J Acquir Immune Defic Syndr 2007; 46:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17672/abstract/25\">",
"      Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007; 370:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17672/abstract/26\">",
"      De Meyer S, Lathouwers E, Dierynck I, et al. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. AIDS 2009; 23:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17672/abstract/27\">",
"      De Meyer SM, Spinosa-Guzman S, Vangeneugden TJ, et al. Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir. J Acquir Immune Defic Syndr 2008; 49:179.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3792 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-B1A854215F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_16_17672=[""].join("\n");
var outline_f17_16_17672=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Abbreviations used",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TREATMENT-NAIVE PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Lopinavir versus nelfinavir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Fosamprenavir versus nelfinavir (SOLO study)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Fosamprenavir versus lopinavir (KLEAN study)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Fosamprenavir versus atazanavir (ALERT trial)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Atazanavir versus lopinavir (CASTLE)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Darunavir versus lopinavir (ARTEMIS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Saquinavir versus lopinavir (GEMINI study)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Summary of selection of PIs in the treatment-naive patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT-EXPERIENCED PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Atazanavir/r versus atazanavir/saquinavir versus lopinavir/r",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Tipranavir versus optimized regimen (RESIST-1 and RESIST-2)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Darunavir versus optimized therapy (POWER trials)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Darunavir versus lopinavir (TITAN)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Treatment-naive patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Treatment-experienced patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/61/986?source=related_link\">",
"      Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=related_link\">",
"      Drug resistance testing in the clinical management of HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=related_link\">",
"      HIV protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/48/4873?source=related_link\">",
"      Overview of HIV drug resistance testing assays",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34218?source=related_link\">",
"      Primer on interpretation of HIV drug resistance testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_16_17673="Neonatal hypoglycemia";
var content_f17_16_17673=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neonatal hypoglycemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/16/17673/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/16/17673/contributors\">",
"     See Wai Chan, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/16/17673/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/16/17673/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/16/17673/contributors\">",
"     Joseph I Wolfsdorf, MB, BCh",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/16/17673/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/16/17673/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/16/17673/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient low blood glucose levels in neonates are common as the source of glucose at delivery changes from a continuous supply from the mother to the intermittent supply from feeds. It is estimated that ten percent of normal term newborns cannot maintain a plasma glucose concentration above 30",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.7",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    if their first feeding is delayed for three to six hours after birth [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Although transient asymptomatic hypoglycemia in healthy infants appears to be part of the normal transition to extrauterine life, persistent or recurrent hypoglycemia can result in neurologic sequelae. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Neurodevelopmental outcome'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <br/>",
"    The pathogenesis, clinical manifestations, evaluation, and management of neonatal hypoglycemia will be discussed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been difficult to define pathologic neonatal hypoglycemia as a precise numerical blood glucose level. Low blood glucose levels normally occur after birth, and most infants are asymptomatic despite very low blood glucose levels. However, some infants are symptomatic at the same or even higher blood glucose levels. This variability is due to a number of factors that affect the infant&rsquo;s response to a decrease in blood glucose level, including the infant&rsquo;s gestational age, postnatal age, the presence of other sources of energy (eg, ketone bodies), and other factors that affect glucose metabolism. Thus, the diagnosis of clinically significant hypoglycemia is dependent on the clinical setting and cannot solely be based on a specific blood glucose level.",
"   </p>",
"   <p>",
"    Ideally, neonatal hypoglycemia would be defined as the blood glucose concentration at which intervention should be initiated to avoid significant morbidity, especially neurologic sequelae. However, this definition remains elusive because the blood glucose level and duration of hypoglycemia associated with poor neurodevelopmental outcome has not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Neurodevelopmental outcome'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In 2000, a consensus statement proposed the use of practical operational thresholds for glucose concentrations at which intervention should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/3\">",
"     3",
"    </a>",
"    ]. These values would provide a margin of safety for the management of neonatal hypoglycemia. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In 2011, a report from the American Academy of Pediatrics (AAP) also discussed the challenge of defining clinically significant hypoglycemia based on blood glucose concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/5\">",
"     5",
"    </a>",
"    ]. This report noted that the generally adopted level used to define neonatal hypoglycemia is less than 47",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and proposed an operational threshold of 45",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    as a target glucose level prior to routine feeds.",
"   </p>",
"   <p>",
"    In our practice, intervention including treatment or further evaluation is considered in all symptomatic neonates and in asymptomatic neonates with a plasma glucose concentration at the following operational thresholds:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Less than 40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.2",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      during the first 24 hours of life for asymptomatic infants and 45",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.5",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      for symptomatic infants",
"     </li>",
"     <li>",
"      Less than 50",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.8",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      after 24 hours of age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, others suggest a higher threshold of plasma glucose of 45",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in the first 24 hours of life [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Glucose concentration measured in whole blood is approximately 15 percent lower than that in plasma and may be further reduced if the hematocrit is high. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Laboratory measurement'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;With loss of the continuous transplacental infusion of glucose, plasma glucose concentration in the healthy term newborn falls during the first two hours after delivery, reaching a nadir that usually is no lower than 40",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    and then stabilizes by four to six hours of age in the range of 45 to 80",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immediately after birth, the plasma glucose concentration is maintained by the breakdown of hepatic glycogen (glycogenolysis) in response to increased plasma epinephrine and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37891?source=see_link\">",
"     glucagon",
"    </a>",
"    concentrations, and falling insulin levels. Glycogen stores are depleted during the first 8 to 12 hours of life. Thereafter, plasma glucose levels are maintained by the synthesis of glucose from lactate, glycerol, and amino acids (gluconeogenesis). As feeds with adequate carbohydrate are established, maintenance of plasma glucose concentrations is no longer solely dependent on gluconeogenesis.",
"   </p>",
"   <p>",
"    Hypoglycemia is caused by a lower rate of glucose production than glucose utilization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16010?source=see_link\">",
"     \"Etiology of hypoglycemia in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inadequate glucose supply",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Inadequate glycogen stores",
"     </li>",
"     <li>",
"      Impaired glucose production (ie, glycogenolysis or gluconeogenesis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased glucose utilization primarily due to hyperinsulinism",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Diminished glucose supply",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179705615\">",
"    <span class=\"h3\">",
"     Inadequate glycogen stores",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inadequate glycogen stores can lead to a diminished supply of glucose. Because glycogen is deposited during the third trimester of pregnancy, infants born prematurely have diminished reserves. Infants with intrauterine growth restriction (IUGR) also have reduced glycogen stores. The mechanism in IUGR is thought to be related to both low intrauterine serum insulin concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/7\">",
"     7",
"    </a>",
"    ] and, if present, chronic intrauterine hypoxia, which results in inefficient anaerobic utilization of glucose. After delivery, a poorly coordinated response of counterregulatory hormones and peripheral insensitivity to these hormones may contribute to hypoglycemia in some infants [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9593?source=see_link\">",
"     \"Small for gestational age infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179705646\">",
"    <span class=\"h3\">",
"     Impaired glucose production",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impaired glucose production is due to the disruption of either glycogenolysis or gluconeogenesis. Hyperinsulinemia also reduces glucose production by impairing glycogen breakdown, which can be overcome with large doses of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37891?source=see_link\">",
"     glucagon",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Glucagon'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3866?source=see_link&amp;anchor=H11#H11\">",
"     \"Pathogenesis, clinical features, and diagnosis of persistent hyperinsulinemic hypoglycemia of infancy\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h4\">",
"     Inborn errors of metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inborn errors of metabolism that may cause neonatal hypoglycemia include (",
"    <a class=\"graphic graphic_table graphicRef76373 \" href=\"UTD.htm?37/63/38908\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disorders of glycogen metabolism resulting from mutations in genes that encode proteins involved in glycogen synthesis, degradation, or regulation of these processes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=see_link\">",
"       \"Overview of inherited disorders of glucose and glycogen metabolism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Disorders of gluconeogenesis (eg, fructose-1,6-bisphosphatase deficiency, pyruvate carboxylase deficiency), defects in amino acid metabolism (eg, maple syrup urine disease, propionic acidemia, and methylmalonic academia), disorders of carbohydrate metabolism (eg, hereditary fructose intolerance, galactosemia), and fatty acid metabolism (eg, medium or long-chain acyl-CoA dehydrogenase deficiency) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link&amp;anchor=H19#H19\">",
"       \"Inborn errors of metabolism: Metabolic emergencies\", section on 'Hypoglycemia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=see_link\">",
"       \"Organic acidemias\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link&amp;anchor=H3682119#H3682119\">",
"       \"Inborn errors of metabolism: Metabolic emergencies\", section on 'Hypoglycemia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h4\">",
"     Endocrine disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deficiency of the hormones that regulate glucose homeostasis result in hypoglycemia. These hormones include cortisol, growth hormone, epinephrine, and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37891?source=see_link\">",
"     glucagon",
"    </a>",
"    . The hormonal deficiency can be isolated or associated with other pituitary hormone deficiencies, or primary adrenocortical insufficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h4\">",
"     Other causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other causes of impaired glucose production resulting in neonatal hypoglycemia include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maternal treatment with beta-sympathomimetic agents (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/51/25397?source=see_link\">",
"       terbutaline",
"      </a>",
"      ) due to interruption of the stimulation of glycogenolysis by epinephrine",
"     </li>",
"     <li>",
"      Hypothermic infants who have diminished availability of glucose and increased rates of glucose utilization",
"     </li>",
"     <li>",
"      Severe hepatic dysfunction due to impairment of both glycogenolysis and gluconeogenesis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Increased glucose utilization due to hyperinsulinism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased glucose utilization primarily results from hyperinsulinemia. The infant of a diabetic mother is the most common clinical situation in which hyperinsulinism causes hyperinsulinemic hypoglycemia. It is postulated that intermittent maternal hyperglycemia causes fetal hyperglycemia, which leads to premature maturation of fetal pancreatic islets and hypertrophy of the beta cells resulting in fetal and neonatal hyperinsulinemia. After termination of the maternal glucose supply at delivery, hypoglycemia from persistent hyperinsulinemia in the newborn usually is transient and typically resolves two to four days after birth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44809?source=see_link\">",
"     \"Infant of a diabetic mother\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other conditions associated with hyperinsulinism and transient hypoglycemia include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beckwith-Wiedemann syndrome ��� 50 percent of patients with Beckwith-Wiedemann syndrome (BWS) have transient or prolonged hypoglycemia caused by hyperinsulinism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24473?source=see_link\">",
"       \"Beckwith-Wiedemann syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Alloimmune hemolytic disease of the newborn. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10665?source=see_link\">",
"       \"Postnatal diagnosis and management of alloimmune hemolytic disease of the newborn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Perinatal asphyxia [",
"      <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29623?source=see_link\">",
"       \"Systemic effects of perinatal asphyxia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Maternal intrapartum treatment with glucose or with anti-hyperglycemia agents such as sulfonylureas.",
"     </li>",
"     <li>",
"      Abrupt interruption of an infusion of a solution with a high glucose concentration. Rarely, glucose infusion through an umbilical artery catheter with its tip near the celiac or superior mesenteric arteries will stimulate excessive insulin release.",
"     </li>",
"     <li>",
"      Persistent hyperinsulinemic hypoglycemia of infancy ��� Infants with persistent hyperinsulinemia typically develop severe hypoglycemia that requires high rates of glucose infusion to maintain normal blood glucose levels in the first postnatal days. Mutations in genes encoding enzymes that control intracellular metabolic pathways of the pancreatic beta cell or transport of cations across the beta cell membrane have been identified in as many as 50 percent of patients. The genes most often affected control the sulfonylurea receptor (SUR1) and the inward rectifier potassium channel (Kir6.2); these proteins form the functional ATP-dependent potassium channel in the beta cell membrane. Persistent hyperinsulinemic hypoglycemia of infancy is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3866?source=see_link\">",
"       \"Pathogenesis, clinical features, and diagnosis of persistent hyperinsulinemic hypoglycemia of infancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Excess exogenous insulin given to newborns with hyperglycemia may result in hypoglycemia [",
"      <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37816?source=see_link&amp;anchor=H19#H19\">",
"       \"Neonatal hyperglycemia\", section on 'Risk of hypoglycemia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Increased glucose utilization without hyperinsulinism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conditions associated with glucose utilization that exceeds production include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Conditions associated with anaerobic glycolysis due to decreased tissue perfusion, poor oxygenation, or biochemical defects that interfere with aerobic glucose metabolism [",
"      <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/12\">",
"       12",
"      </a>",
"      ]. The energy (ATP) per molecule of glucose produced by anaerobic glycolysis is only about 5 percent of that produced by aerobic glucose metabolism.",
"     </li>",
"     <li>",
"      Although the mechanism is not known, sepsis is sometimes associated with hypoglycemia. Proposed contributing factors include increased glucose utilization, depleted glycogen stores, or impaired gluconeogenesis.",
"     </li>",
"     <li>",
"      Hypoglycemia associated with polycythemia may result from greater glucose utilization by the increased mass of red blood cells.",
"     </li>",
"     <li>",
"      Increased glucose consumption can occur with heart failure or perinatal asphyxia; hyperinsulinism has also been documented in infants who experience perinatal asphyxia [",
"      <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Neuroglycopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transport protein GLUT1 facilitates glucose diffusion across blood vessels into the brain and cerebrospinal fluid (CSF). Although blood glucose concentrations are normal, deficiency of GLUT1 results in low CSF glucose concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with hypoglycemia frequently are asymptomatic and hypoglycemia is often detected by routine monitoring of blood glucose in at-risk infants.",
"   </p>",
"   <p>",
"    In the symptomatic infant, signs are nonspecific and include [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Jitteriness",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      tremors",
"     </li>",
"     <li>",
"      Hypotonia",
"     </li>",
"     <li>",
"      Change in level of consciousness (irritability, lethargy, or stupor)",
"     </li>",
"     <li>",
"      Apnea, bradycardia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cyanosis",
"     </li>",
"     <li>",
"      Tachypnea",
"     </li>",
"     <li>",
"      Poor suck or poor feeding",
"     </li>",
"     <li>",
"      Weak or high-pitched cry",
"     </li>",
"     <li>",
"      Hypothermia",
"     </li>",
"     <li>",
"      Seizures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because these are nonspecific signs and symptoms, further evaluation for other possible causes (eg, sepsis) should be conducted if symptoms do not resolve after normalization of the blood glucose concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6410?source=see_link\">",
"     \"Clinical features and diagnosis of sepsis in term and late preterm infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179706548\">",
"    <span class=\"h2\">",
"     Who should be evaluated",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood glucose concentration should be measured in infants at risk for hypoglycemia and in infants who exhibit signs or symptoms consistent with hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infants at risk for hypoglycemia include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Premature infants",
"     </li>",
"     <li>",
"      Infants who are large or small for gestational age",
"     </li>",
"     <li>",
"      Infants of diabetic mothers",
"     </li>",
"     <li>",
"      Infants who require intensive care (eg, sepsis and asphyxia)",
"     </li>",
"     <li>",
"      Infants whose mothers were treated with beta adrenergic or oral hypoglycemic agents",
"     </li>",
"     <li>",
"      Infants with polycythemia (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36968?source=see_link\">",
"       \"Neonatal polycythemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A prospective study of at-risk neonates (ie, large or small for gestational age, infant of diabetic mother, late preterm infants) with a gestational age of 35 weeks or greater, using a higher threshold for hypoglycemia, reported that one-half of these neonates had at least one episode of hypoglycemia (blood glucose: 47",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.6",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    about 20 percent had severe hypoglycemia (blood glucose: 36",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    and 20 percent had more than one hypoglycemic episode [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/14\">",
"     14",
"    </a>",
"    ]. Most of the low glucose measurements occurred within the first 24 hours of life and were in asymptomatic infants.",
"   </p>",
"   <p>",
"    Blood glucose concentration should also be monitored at least weekly in infants receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    , even if they appear stable. We usually maintain plasma glucose levels greater than 50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.8",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    to provide a margin of safety. These infants have high plasma insulin concentrations and, thus, have suppressed lipolysis and ketogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We do",
"    <strong>",
"     not",
"    </strong>",
"    routinely monitor blood glucose concentrations in healthy asymptomatic term infants born after an uncomplicated pregnancy and delivery. Newborns normally mobilize fat and form ketone bodies during fasting, and the fetal and neonatal brain can use alternative fuels (ketone bodies and lactate) for oxidative metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. This adaptive mechanism may explain why breast-fed term infants remain asymptomatic despite typically having lower blood glucose concentrations but higher concentrations of ketone bodies than formula-fed infants [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/18\">",
"     18",
"    </a>",
"    ]. Although term breast-fed infants may be able to tolerate relatively low plasma glucose levels without clinical manifestations or neurologic sequelae, the extent to which higher concentrations of ketone bodies is protective is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     How and when is glucose screening performed",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucose monitoring is performed within one to two hours after birth in infants who are at-risk for hypoglycemia or whenever symptoms consistent with hypoglycemia occur. Samples should be obtained before feedings. Surveillance is continued for the first 12 to 24 hours of life. Blood glucose monitoring should continue after 24 hours of life in infants with low plasma glucose concentrations (less than 45",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    2.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    until feedings are well established and glucose values have normalized [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most nurseries perform capillary blood glucose measurements with a point of care glucose meter as a rapid screening method. However, glucose meters show large variations in values compared to laboratory methods, especially at low glucose concentrations, and are of unproven reliability to document hypoglycemia in newborns [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Thus, the plasma glucose concentration in an infant with a low glucose value determined by a glucose meter should be confirmed by laboratory measurement [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/5\">",
"     5",
"    </a>",
"    ]. Likewise, laboratory confirmation of the plasma glucose concentration should be performed in any infant who show signs consistent with hypoglycemia. However, treatment is started immediately after the blood sample is obtained and before confirmatory results are available.",
"   </p>",
"   <p>",
"    Continuous glucose monitoring using a sensor that measures interstitial glucose concentration was reported to be reliable (when compared to blood glucose measurement), safe, and tolerable [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. However, it is unclear how to interpret the clinical significance of low interstitial blood glucose levels and whether treatment should be initiated. Further studies are needed to determine whether continuous interstitial glucose monitoring has a useful role in the screening and management of neonatal hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Laboratory measurement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory measurement of glucose concentration is affected by the type of sample. Glucose concentration measured in whole blood is approximately 15 percent lower than that in plasma and may be further reduced if the hematocrit is high. Prompt analysis should be performed because blood glucose values can decrease by 15 to 20",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    per hour in samples at room temperature (without separation of plasma).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Persistent hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;If hypoglycemia is severe (eg, associated with seizures or altered level of consciousness) in an otherwise healthy infant or if glucose infusions of more than 8 to 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per minute are needed to maintain plasma glucose concentrations greater than 50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.8",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    for longer than one week, the infant should be evaluated for rare causes of hypoglycemia.",
"   </p>",
"   <p>",
"    Further evaluation should also be considered in any infant with persistent hypoglycemia, and physical abnormalities that are suggestive of specific underlying etiologies. These include hypotonia and hepatomegaly seen in patients with disorders of glycogen metabolism, and omphalocele, macroglossia, and macrosomia seen in infants with Beckwith-Wiedemann syndrome (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16010?source=see_link\">",
"     \"Etiology of hypoglycemia in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=see_link\">",
"     \"Overview of inherited disorders of glucose and glycogen metabolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24473?source=see_link\">",
"     \"Beckwith-Wiedemann syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, a family history of unexplained neonatal death or sudden infant death syndrome, or unexplained delay in psychomotor development should prompt further investigation. &nbsp;",
"   </p>",
"   <p>",
"    In these infants, the following blood measurements should be obtained at the time of hypoglycemia: serum insulin, cortisol, growth hormone, and amino acids. Obtaining these tests after the hypoglycemia has resolved is not helpful to establish an etiology. Ketones, reducing substances, and organic acids are measured in urine. Consultation with a pediatric endocrinologist is recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of hypoglycemia is directed toward prevention or resolution of symptoms due to hypoglycemia. As discussed previously, the following optional thresholds are used for asymptomatic neonates in",
"    <strong>",
"     our practice",
"    </strong>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Less than 40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.2",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      during the first 24 hours of life",
"     </li>",
"     <li>",
"      Less than 50",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.8",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      after 24 hours of age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other centers use a higher threshold of plasma glucose of 45",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in the first 24 hours of life. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Definition'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The treatment of hypoglycemia is a stepwise process depending on the presence or absence of symptoms and signs, and the response of the infant at each step as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral feedings of breast milk or formula in asymptomatic infants.",
"     </li>",
"     <li>",
"      Parenteral glucose infusion at a rate of at least 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per minute for infants who are symptomatic, with severe hypoglycemia (plasma glucose less than 25",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [1.4",
"      <span class=\"nowrap\">",
"       mmol/L]),",
"      </span>",
"      who are unable to be enterally fed or who experience persistent hypoglycemia despite frequent oral feedings. If hypoglycemia is persistent, glucose infusion rates can be increased and glucose infusion rates may exceed 12",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per minute.",
"     </li>",
"     <li>",
"      Administration of glucocorticoid therapy in infants requiring a glucose infusion rate of 12",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per minute or greater for two or more days. &nbsp;",
"     </li>",
"     <li>",
"      Administration of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37891?source=see_link\">",
"       glucagon",
"      </a>",
"      in rare patients who remain hypoglycemic despite continuous parenteral glucose infusion and administration of glucocorticoid therapy while undergoing further evaluation and treatment.",
"     </li>",
"     <li>",
"      Other therapeutic options for persistent hyperinsulinemic hypoglycemia include drug therapy (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/11/13492?source=see_link\">",
"       diazoxide",
"      </a>",
"      ), and pancreatectomy in patients with hyperinsulinemia unresponsive to medical management. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12295?source=see_link&amp;anchor=H31077305#H31077305\">",
"       \"Treatment and complications of persistent hyperinsulinemic hypoglycemia of infancy\", section on 'Diazoxide'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12295?source=see_link&amp;anchor=H7#H7\">",
"       \"Treatment and complications of persistent hyperinsulinemic hypoglycemia of infancy\", section on 'Surgical therapy'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      In infants with persistent hypoglycemia, further evaluation is performed to determine the cause of hypoglycemia. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Persistent hypoglycemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The above approach is consistent with that outlined by the 2011 AAP clinical report, which uses slightly different blood glucose thresholds, as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Parenteral glucose infusion for infants who are symptomatic with blood glucose levels &lt;40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.2",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      An initial oral feeding is given to the following asymptomatic infants based on the age of the neonate and blood glucose level, and the level is rechecked in one hour:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Infants less than 4 hours of life and blood glucose &lt;25",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.4",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      If blood glucose fails to increase, parental glucose is administered. If the blood glucose increases to 25 to 40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.4 to 2.2",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      oral feeding or parenteral glucose is given.",
"     </li>",
"     <li>",
"      Infants between 4 and 24 hours of life and blood glucose &lt;35",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.9",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      If blood glucose fails to increase, parental glucose is administered. If the blood glucose increases to 35 to 45",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.9 to 2.5",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      oral feeding or parenteral glucose is given.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Oral feeds",
"    </span>",
"    &nbsp;&mdash;&nbsp;Healthy infants are fed as soon as possible after birth. Although the immediate effect of early feeding was negligible in one small study, establishing feeding is a natural process and may prevent subsequent hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/24\">",
"     24",
"    </a>",
"    ]. Infants who are at risk for hypoglycemia should be fed within the first hour of life, and a blood glucose level should be obtained 30 minutes after the feed [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the blood glucose is less than 40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.2",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    on a screening measurement in an asymptomatic term infant, we obtain a blood sample for laboratory measurement of plasma glucose concentration and immediately offer breast or formula feeding. We monitor the blood glucose level frequently, starting 20 to 30 minutes after the feeding, and we continue to offer feedings at two- to three-hour intervals.",
"   </p>",
"   <p>",
"    The same management approach is used in asymptomatic premature infants [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/3\">",
"     3",
"    </a>",
"    ], although parenteral nutrition, which includes glucose, is frequently used to supplement enteral feedings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/8/19593?source=see_link\">",
"     \"Approach to enteral nutrition in the premature infant\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/8/19593?source=see_link&amp;anchor=H776783108#H776783108\">",
"     \"Approach to enteral nutrition in the premature infant\", section on 'Our approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Parenteral glucose infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parenteral glucose therapy is administered for the following indications:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptomatic infants",
"     </li>",
"     <li>",
"      Neonates with severe hypoglycemia defined as plasma glucose concentration less than 20 to 25",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.1 to 1.4",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/3\">",
"       3",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Neonates with persistent hypoglycemia after feeding defined as plasma glucose concentration below 40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.2",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Neonates who are unable to feed or intolerant of enteral feedings with plasma glucose concentrations below 40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.2",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Parenteral glucose therapy is administered as an initial bolus infusion of 200",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    glucose (2",
"    <span class=\"nowrap\">",
"     ml/kg",
"    </span>",
"    of 10 percent dextrose in water) over one minute, followed by a glucose infusion at 6 to 8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per minute [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/25\">",
"     25",
"    </a>",
"    ]. The small bolus minimizes hyperglycemia that can provoke insulin secretion and possibly prolong hypoglycemia.",
"   </p>",
"   <p>",
"    We check the blood glucose concentration 20 minutes after the bolus infusion and adjust the infusion rate or dextrose concentration as needed to maintain plasma glucose concentration greater than 50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.8",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    Although the ideal level remains uncertain, this operational therapeutic threshold allows a margin of safety. Infants who depend upon high infusion rates or a dextrose concentration greater than 12.5 percent require placement of a central venous catheter through the umbilicus or a peripheral vein.",
"   </p>",
"   <p>",
"    When the glucose concentration is stable, the glucose infusion rate can be tapered slowly as feedings are advanced. The taper typically occurs over a period of two to four days. While the intravenous glucose infusion is tapered, the pre-prandial blood glucose level should be monitored every three to four hours depending upon the feeding schedule.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Persistent hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In infants with persistent hypoglycemia, further evaluation is performed to determine the cause of hypoglycemia. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Persistent hypoglycemia'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoid therapy is considered in infants whose hypoglycemia persists after two to three days of receiving a glucose infusion greater than 12",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per minute. The proposed mechanism of action of glucocorticoids is stimulation of gluconeogenesis and reduction in peripheral glucose utilization. We give",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day divided in two doses orally or intravenously); alternatively,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day orally or intravenously) may be used. Glucose levels usually will become stable over several days, and the glucocorticoid therapy can be rapidly tapered. We measure serum cortisol and insulin levels before beginning glucocorticoid treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Glucagon",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37891?source=see_link\">",
"     Glucagon",
"    </a>",
"    is used in the rare neonate whose hypoglycemia persists despite parenteral infusion of glucose and administration of glucocorticoid therapy.",
"   </p>",
"   <p>",
"    A wide range of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37891?source=see_link\">",
"     glucagon",
"    </a>",
"    doses (20 to 200",
"    <span class=\"nowrap\">",
"     mcg/kg,",
"    </span>",
"    maximum dose of 1 mg) has been described in case reports and series of neonates and infants as an emergent treatment for acute severe hypoglycemia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The lower dose, 20",
"      <span class=\"nowrap\">",
"       mcg/kg,",
"      </span>",
"      administered subcutaneously has been effective as emergent outpatient treatment for acute hypoglycemia in patients with type 1 diabetes who are below two years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. In the largest reported case series consisting of 55 newborns cared for at a tertiary Canadian center over a five-year period, intravenous",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37891?source=see_link\">",
"       glucagon",
"      </a>",
"      infusion at a dose of 10 to 20",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per hour was effective in the treatment of persistent significant hypoglycemia due to a variety of causes (eg, asphyxia, intrauterine growth restriction, prematurity, and infant of diabetic mother) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An earlier small case series reported that a single intravenous 200",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      bolus was effective in the treatment of hypoglycemia in neonates [",
"      <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon the currently available literature and our own clinical experience, we administer",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37891?source=see_link\">",
"     glucagon",
"    </a>",
"    at an initial dose of 20 to 30",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    to infants with persistent hypoglycemia, despite parenteral glucose infusion and glucocorticoid therapy. Glucagon can be given as a slow intravenous push over one minute, or by intramuscular or subcutaneous injection. Intramuscular or subcutaneous administration is helpful as a temporizing measure when intravenous access is difficult to establish. A rise in blood glucose should occur within 15 to 30 minutes of administration and should last approximately two hours. Blood glucose levels should be monitored, as there may be a rebound hypoglycemia. If the serum glucose does not rise within 20 minutes of glucagon administration, then a repeat dose of glucagon is given. A failure to respond to glucagon raises the possibility of a glycogen storage disorder or defect in glycogen synthesis. In these patients, further evaluation is warranted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=see_link\">",
"     \"Overview of inherited disorders of glucose and glycogen metabolism\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37891?source=see_link\">",
"     Glucagon",
"    </a>",
"    should",
"    <strong>",
"     not",
"    </strong>",
"    be used in infants who are small for gestational age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Persistent hyperinsulinism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of persistent hyperinsulinemic hypoglycemia of infancy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3866?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of persistent hyperinsulinemic hypoglycemia of infancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     NEURODEVELOPMENTAL OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic hypoglycemia can result in brain injury detected by magnetic resonance imaging (MRI), although there are no available data that define the glucose concentration or the duration of hypoglycemia associated with damage.",
"   </p>",
"   <p>",
"    A systematic review of the literature published in 2006 reported inconclusive evidence on the effect of neonatal hypoglycemia on neurodevelopment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/30\">",
"     30",
"    </a>",
"    ]. Two subsequent studies using magnetic resonance brain imaging suggest an association between hypoglycemia and brain injury in term infants [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Although it remains uncertain whether timely treatment of hypoglycemia will prevent brain injury and poor developmental outcome, we suggest that symptomatic neonatal hypoglycemia be aggressively treated given the potential significant adverse effects based on the currently available data.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H279830189\">",
"    <span class=\"h2\">",
"     Preterm infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;In preterm infants, controversy exists as to whether asymptomatic hypoglycemia causes neurologic injury and whether glucose concentrations requiring intervention should be lower in premature than term infants.",
"   </p>",
"   <p>",
"    Several studies report neurodevelopmental sequelae due to repeated or prolonged episodes of neonatal hypoglycemia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Retrospective data analysis of a multicenter trial in premature infants showed a correlation between prolonged hypoglycemia (plasma glucose concentrations less than 47",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [2.6",
"      <span class=\"nowrap\">",
"       mmol/L]",
"      </span>",
"      on five different days during the first two months of age) and lower Bayley mental and psychomotor scores at 18 months corrected age [",
"      <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/33\">",
"       33",
"      </a>",
"      ]. Developmental delay or cerebral palsy was 3.5 times greater (95% CI 1.3-9.4) in the hypoglycemic infants. However, the frequency of glucose testing was variable and occurred more often in sicker infants. Furthermore, only arithmetic and motor scores were lower in hypoglycemic infants at 7.5 to 8 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of pre-school age children who were born moderately premature (gestational age 32 to less than 36 weeks), multivariate analysis showed that hypoglycemia was associated with increased incidence of parent-reported developmental delay when the children were 43 to 49 months old (odds ratio: 2.19, 95% CI 1.08-4.46) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The long-term impairment of neurodevelopment may be greater in preterm infants with repeated hypoglycemic episodes who are also small for gestational age (SGA). In a prospective study of 85 SGA preterm infants, repeated episodes of hypoglycemia were associated with a smaller head circumference at 18 months corrected age and lower psychometric testing scores at 3.5 and five years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, a study of premature infants (gestational age &lt;32 weeks) with daily measurements of blood glucose obtained at a fixed time each morning for the first 10 days of life reported no differences in developmental status or physical disability based on psychometric assessment between 47 patients who had neonatal blood glucose levels &le;45",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.5",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      on &ge;3 days compared with matched control patients during follow-up at 2 and 15 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?17/16/17673/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/6/18529?source=see_link\">",
"       \"Patient information: Newborn hypoglycemia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15017572\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient low blood glucose levels are common after birth as the glucose supply to neonates changes from a continuous transplacental supply from the mother to an intermittent supply from feeds. Persistent or recurrent hypoglycemia can result in neurologic sequelae. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Neurodevelopmental outcome'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It has been difficult to establish a single numerical blood glucose level that accurately predicts significant neonatal hypoglycemia at which intervention should be initiated to prevent morbidity. As a result, operational thresholds have been proposed to provide a margin of safety until additional data become available to provide a more precise definition. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest the following operational plasma glucose threshold for further evaluation and intervention in asymptomatic neonates (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Others use different plasma glucose thresholds including one approach that uses 36",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in asymptomatic infants, and 45",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.5",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in symptomatic infants. The American Academy of Pediatrics uses an operational level of 45",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.5",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in asymptomatic neonates. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Less than 40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.2",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      during the first 24 hours of life",
"     </li>",
"     <li>",
"      Less than 50",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.8",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      after 24 hours of age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypoglycemia is caused by a rate of glucose production that is lower than the rate of glucose utilization. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16010?source=see_link\">",
"       \"Etiology of hypoglycemia in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In neonates, diminished glucose supply is due to inadequate glycogen stores or impaired glucose production (ie, glycogenolysis or gluconeogenesis). (See",
"      <a class=\"local\" href=\"#H179705615\">",
"       'Inadequate glycogen stores'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Increased glucose utilization is primarily due to various causes of hyperinsulinism, hormonal deficiencies (eg, cortisol and growth hormone), hypothermia, or maternal treatment with insulin or antihyperglycemic agents. Disorders that result in increased glucose utilization without increased insulin levels include sepsis, polycythemia, and conditions associated with poor tissue perfusion or oxygenation. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Increased glucose utilization due to hyperinsulinism'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Increased glucose utilization without hyperinsulinism'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants with hypoglycemia are frequently asymptomatic or have nonspecific symptoms and signs, which include",
"      <span class=\"nowrap\">",
"       jitteriness/tremors,",
"      </span>",
"      hypotonia, changes in level of consciousness,",
"      <span class=\"nowrap\">",
"       apnea/bradycardia,",
"      </span>",
"      cyanosis, tachypnea, poor suck or feeding, hypothermia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      seizures. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Blood glucose should be measured in infants who are symptomatic or at risk for hypoglycemia. At-risk infants include premature infants, infants who are large or small for gestational age, infants of mothers with diabetes or who required beta-adrenergic or oral antihyperglycemic agents, and infants who require intensive care or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"       total parenteral nutrition",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H179706548\">",
"       'Who should be evaluated'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Glucose monitoring is performed within one to two hours after birth in infants who are at-risk for hypoglycemia or in infants with symptoms consistent with hypoglycemia. Most nurseries perform point of care capillary blood glucose measurements with a glucose meter as a rapid screening method. A low screening glucose value should always be confirmed by laboratory measurement. Treatment is initiated after the blood sample is obtained, while awaiting confirmatory laboratory results. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'How and when is glucose screening performed'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest the following stepwise management approach for neonatal hypoglycemia, which is dependent upon the presence or absence of symptoms, and the response of the infant at each step (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Oral feedings of breast milk or formula in asymptomatic infants.",
"     </li>",
"     <li>",
"      Parenteral glucose infusion of at least 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per minute in infants who are symptomatic, have severe hypoglycemia (plasma glucose &lt;25",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [1.4",
"      <span class=\"nowrap\">",
"       mmol/L]),",
"      </span>",
"      unable to feed, or who have persistent hypoglycemia despite frequent oral feedings.",
"     </li>",
"     <li>",
"      Administration of glucocorticoids in infants with persistent hypoglycemia after two to three days of glucose infusion greater than 12",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per minute.",
"     </li>",
"     <li>",
"      Administration of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37891?source=see_link\">",
"       glucagon",
"      </a>",
"      in the rare patient in whom hypoglycemia persists despite continuous parenteral glucose infusion and administration of glucocorticoids.",
"     </li>",
"     <li>",
"      Oral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/11/13492?source=see_link\">",
"       diazoxide",
"      </a>",
"      in patients with persistent hyperinsulinemic hypoglycemia of infancy.",
"     </li>",
"     <li>",
"      Further evaluation is needed to determine the cause of persistent hypoglycemia including hyperinsulinemic conditions. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Persistent hypoglycemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants who require glucose infusions of greater than 8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per minute to maintain plasma glucose concentrations greater than 50",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.8",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      for more than one week should be evaluated by a pediatric endocrinologist for unusual causes of hypoglycemia. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Persistent hypoglycemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17673/abstract/1\">",
"      Stanley CA, Baker L. The causes of neonatal hypoglycemia. N Engl J Med 1999; 340:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17673/abstract/2\">",
"      Lubchenco LO, Bard H. Incidence of hypoglycemia in newborn infants classified by birth weight and gestational age. Pediatrics 1971; 47:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17673/abstract/3\">",
"      Cornblath M, Hawdon JM, Williams AF, et al. Controversies regarding definition of neonatal hypoglycemia: suggested operational thresholds. Pediatrics 2000; 105:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17673/abstract/4\">",
"      Hay WW Jr, Raju TN, Higgins RD, et al. Knowledge gaps and research needs for understanding and treating neonatal hypoglycemia: workshop report from Eunice Kennedy Shriver National Institute of Child Health and Human Development. J Pediatr 2009; 155:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17673/abstract/5\">",
"      Committee on Fetus and Newborn, Adamkin DH. Postnatal glucose homeostasis in late-preterm and term infants. Pediatrics 2011; 127:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17673/abstract/6\">",
"      Srinivasan G, Pildes RS, Cattamanchi G, et al. Plasma glucose values in normal neonates: a new look. J Pediatr 1986; 109:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17673/abstract/7\">",
"      Economides DL, Proudler A, Nicolaides KH. Plasma insulin in appropriate- and small-for-gestational-age fetuses. Am J Obstet Gynecol 1989; 160:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17673/abstract/8\">",
"      Hawdon JM, Weddell A, Aynsley-Green A, Ward Platt MP. Hormonal and metabolic response to hypoglycaemia in small for gestational age infants. Arch Dis Child 1993; 68:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17673/abstract/9\">",
"      Worthen HG, al Ashwal A, Ozand PT, et al. Comparative frequency and severity of hypoglycemia in selected organic acidemias, branched chain amino acidemia, and disorders of fructose metabolism. Brain Dev 1994; 16 Suppl:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17673/abstract/10\">",
"      Collins JE, Leonard JV. Hyperinsulinism in asphyxiated and small-for-dates infants with hypoglycaemia. Lancet 1984; 2:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17673/abstract/11\">",
"      Sinclair JC, Bottino M, Cowett RM. Interventions for prevention of neonatal hyperglycemia in very low birth weight infants. Cochrane Database Syst Rev 2009; :CD007615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17673/abstract/12\">",
"      Sue CM, Hirano M, DiMauro S, De Vivo DC. Neonatal presentations of mitochondrial metabolic disorders. Semin Perinatol 1999; 23:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17673/abstract/13\">",
"      Seidner G, Alvarez MG, Yeh JI, et al. GLUT-1 deficiency syndrome caused by haploinsufficiency of the blood-brain barrier hexose carrier. Nat Genet 1998; 18:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17673/abstract/14\">",
"      Harris DL, Weston PJ, Harding JE. Incidence of neonatal hypoglycemia in babies identified as at risk. J Pediatr 2012; 161:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17673/abstract/15\">",
"      Adam PA, R&auml;ih&auml; N, Rahiala EL, Kekom&auml;ki M. Oxidation of glucose and D-B-OH-butyrate by the early human fetal brain. Acta Paediatr Scand 1975; 64:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17673/abstract/16\">",
"      de Boissieu D, Rocchiccioli F, Kalach N, Bougn&egrave;res PF. Ketone body turnover at term and in premature newborns in the first 2 weeks after birth. Biol Neonate 1995; 67:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17673/abstract/17\">",
"      Vannucci RC, Nardis EE, Vannucci SJ, Campbell PA. Cerebral carbohydrate and energy metabolism during hypoglycemia in newborn dogs. Am J Physiol 1981; 240:R192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17673/abstract/18\">",
"      Hawdon JM, Ward Platt MP, Aynsley-Green A. Patterns of metabolic adaptation for preterm and term infants in the first neonatal week. Arch Dis Child 1992; 67:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17673/abstract/19\">",
"      Balion C, Grey V, Ismaila A, et al. Screening for hypoglycemia at the bedside in the neonatal intensive care unit (NICU) with the Abbott PCx glucose meter. BMC Pediatr 2006; 6:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17673/abstract/20\">",
"      Rosenthal M, Ugele B, Lipowsky G, K&uuml;ster H. The Accutrend sensor glucose analyzer may not be adequate in bedside testing for neonatal hypoglycemia. Eur J Pediatr 2006; 165:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17673/abstract/21\">",
"      Harris DL, Battin MR, Weston PJ, Harding JE. Continuous glucose monitoring in newborn babies at risk of hypoglycemia. J Pediatr 2010; 157:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17673/abstract/22\">",
"      Beardsall K, Vanhaesebrouck S, Ogilvy-Stuart AL, et al. Validation of the continuous glucose monitoring sensor in preterm infants. Arch Dis Child Fetal Neonatal Ed 2013; 98:F136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17673/abstract/23\">",
"      Hay WW Jr, Rozance PJ. Continuous glucose monitoring for diagnosis and treatment of neonatal hypoglycemia. J Pediatr 2010; 157:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17673/abstract/24\">",
"      Sweet DG, Hadden D, Halliday HL. The effect of early feeding on the neonatal blood glucose level at 1-hour of age. Early Hum Dev 1999; 55:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17673/abstract/25\">",
"      Lilien LD, Pildes RS, Srinivasan G, et al. Treatment of neonatal hypoglycemia with minibolus and intraveous glucose infusion. J Pediatr 1980; 97:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17673/abstract/26\">",
"      Haymond MW, Schreiner B. Mini-dose glucagon rescue for hypoglycemia in children with type 1 diabetes. Diabetes Care 2001; 24:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17673/abstract/27\">",
"      Hartley M, Thomsett MJ, Cotterill AM. Mini-dose glucagon rescue for mild hypoglycaemia in children with type 1 diabetes: the Brisbane experience. J Paediatr Child Health 2006; 42:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17673/abstract/28\">",
"      Miralles RE, Lodha A, Perlman M, Moore AM. Experience with intravenous glucagon infusions as a treatment for resistant neonatal hypoglycemia. Arch Pediatr Adolesc Med 2002; 156:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17673/abstract/29\">",
"      Hawdon JM, Aynsley-Green A, Ward Platt MP. Neonatal blood glucose concentrations: metabolic effects of intravenous glucagon and intragastric medium chain triglyceride. Arch Dis Child 1993; 68:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17673/abstract/30\">",
"      Boluyt N, van Kempen A, Offringa M. Neurodevelopment after neonatal hypoglycemia: a systematic review and design of an optimal future study. Pediatrics 2006; 117:2231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17673/abstract/31\">",
"      Burns CM, Rutherford MA, Boardman JP, Cowan FM. Patterns of cerebral injury and neurodevelopmental outcomes after symptomatic neonatal hypoglycemia. Pediatrics 2008; 122:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17673/abstract/32\">",
"      Tam EW, Widjaja E, Blaser SI, et al. Occipital lobe injury and cortical visual outcomes after neonatal hypoglycemia. Pediatrics 2008; 122:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17673/abstract/33\">",
"      Lucas A, Morley R, Cole TJ. Adverse neurodevelopmental outcome of moderate neonatal hypoglycaemia. BMJ 1988; 297:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17673/abstract/34\">",
"      Cornblath M, Schwartz R. Outcome of neonatal hypoglycaemia. Complete data are needed. BMJ 1999; 318:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17673/abstract/35\">",
"      Kerstjens JM, Bocca-Tjeertes IF, de Winter AF, et al. Neonatal morbidities and developmental delay in moderately preterm-born children. Pediatrics 2012; 130:e265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17673/abstract/36\">",
"      Duvanel CB, Fawer CL, Cotting J, et al. Long-term effects of neonatal hypoglycemia on brain growth and psychomotor development in small-for-gestational-age preterm infants. J Pediatr 1999; 134:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17673/abstract/37\">",
"      Tin W, Brunskill G, Kelly T, Fritz S. 15-year follow-up of recurrent \"hypoglycemia\" in preterm infants. Pediatrics 2012; 130:e1497.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5053 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-219.243.220.100-537ACF1ECA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_16_17673=[""].join("\n");
var outline_f17_16_17673=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15017572\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Diminished glucose supply",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H179705615\">",
"      - Inadequate glycogen stores",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H179705646\">",
"      - Impaired glucose production",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Inborn errors of metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Endocrine disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Increased glucose utilization due to hyperinsulinism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Increased glucose utilization without hyperinsulinism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Neuroglycopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H179706548\">",
"      Who should be evaluated",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      How and when is glucose screening performed",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Laboratory measurement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Persistent hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Oral feeds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Parenteral glucose infusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Persistent hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Glucagon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Persistent hyperinsulinism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      NEURODEVELOPMENTAL OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H279830189\">",
"      Preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15017572\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5053\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5053|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/63/38908\" title=\"table 1\">",
"      Laboratory findings inborn errors of metabolism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/8/19593?source=related_link\">",
"      Approach to enteral nutrition in the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24473?source=related_link\">",
"      Beckwith-Wiedemann syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6410?source=related_link\">",
"      Clinical features and diagnosis of sepsis in term and late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16010?source=related_link\">",
"      Etiology of hypoglycemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=related_link\">",
"      Inborn errors of metabolism: Metabolic emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44809?source=related_link\">",
"      Infant of a diabetic mother",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37816?source=related_link\">",
"      Neonatal hyperglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36968?source=related_link\">",
"      Neonatal polycythemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=related_link\">",
"      Organic acidemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=related_link\">",
"      Overview of inherited disorders of glucose and glycogen metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3866?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of persistent hyperinsulinemic hypoglycemia of infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/6/18529?source=related_link\">",
"      Patient information: Newborn hypoglycemia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10665?source=related_link\">",
"      Postnatal diagnosis and management of alloimmune hemolytic disease of the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9593?source=related_link\">",
"      Small for gestational age infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29623?source=related_link\">",
"      Systemic effects of perinatal asphyxia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12295?source=related_link\">",
"      Treatment and complications of persistent hyperinsulinemic hypoglycemia of infancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_16_17674="Interpersonal Psychotherapy (IPT) for depressed adults: Indications, theoretical foundation, general concepts, and efficacy";
var content_f17_16_17674=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Interpersonal Psychotherapy (IPT) for depressed adults: Indications, theoretical foundation, general concepts, and efficacy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/16/17674/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/16/17674/contributors\">",
"     Holly A Swartz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/16/17674/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/16/17674/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/16/17674/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/16/17674/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/16/17674/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H91116969\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interpersonal Psychotherapy (IPT) is a time-limited psychotherapy for treating depression [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The therapy focuses upon improving problematic interpersonal relationships or circumstances that are directly related to the current depressive episode. Interpersonal relationships and depressive symptoms appear to affect each other in a reciprocal manner [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. Improvement of interpersonal functioning reduces symptoms, which leads to additional spontaneous improvement of interpersonal functioning, which in turn reduces depressive symptoms further.",
"   </p>",
"   <p>",
"    IPT was developed in the 1970s as a treatment for depression and for many years was used only by investigators in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/8\">",
"     8",
"    </a>",
"    ]. Demonstrated success in multiple studies eventually led clinicians to discover that IPT is a practical, user-friendly treatment for many different types of depressed patients, including pregnant, postpartum, and primary care patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neuroimaging studies using sequential single photon emission computed tomography (SPECT) and positron emission tomography (PET) suggest that successful treatment of major depression with IPT leads to changes in brain function [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Many of these changes overlap with changes in brain function seen in patients treated with an antidepressant, including regional brain metabolic abnormalities that tended to normalize with treatment.",
"   </p>",
"   <p>",
"    Clinical guidelines endorse IPT monotherapy for treatment of mild to moderate depression [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/9,12,13\">",
"     9,12,13",
"    </a>",
"    ]. In addition, IPT is used to treat other psychiatric illnesses, including bipolar disorder, eating disorders, and anxiety disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the indications, theoretical foundation, general concepts, and efficacy of IPT for treating depressed adults. Specific IPT interventions and procedures for treating depressed adults are discussed separately, as are other treatments of depression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/20/4425?source=see_link\">",
"     \"Interpersonal Psychotherapy (IPT) for depressed adults: Specific interventions and techniques\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link\">",
"     \"Treatment of resistant depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91120529\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interpersonal Psychotherapy (IPT) is indicated for depressed patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/9,12,13\">",
"     9,12,13",
"    </a>",
"    ]. The primary goals of treatment are symptom remission and improved interpersonal functioning.",
"   </p>",
"   <p>",
"    As with all psychotherapies, the patient must have the necessary motivation, interest, and cognitive capacity to participate in treatment and complete assigned tasks.",
"   </p>",
"   <p>",
"    There are no specific contraindications to IPT. However, patients must be able to tolerate elicitation of strong affects such as sadness and anxiety, which may occur during treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/13\">",
"     13",
"    </a>",
"    ]. Psychotic patients are not candidates for most psychotherapies, including IPT.",
"   </p>",
"   <p>",
"    IPT may be used alone or in combination with an antidepressant medication, depending upon symptom severity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/14\">",
"     14",
"    </a>",
"    ]. Monotherapy with IPT is often used to treat mild to moderate depression. In addition, IPT alone may be helpful for more severely ill patients. However, patients with moderate to severe depression, especially moderate to severe suicidal ideation or moderate to severe neurovegetative symptoms (decreased sleep, appetite, energy, and libido), generally require pharmacotherapy in addition to IPT [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/9,12,15\">",
"     9,12,15",
"    </a>",
"    ]. Treating patients with IPT plus medication is supported by meta-analyses that found combination treatment was significantly better than medication alone for treatment of depressive disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Combining IPT with pharmacotherapy is readily accomplished because IPT is based upon the medical model. The decision to use medication plus IPT is primarily based upon symptom severity, and secondarily past history, patient preference, and cost. (See",
"    <a class=\"local\" href=\"#H91117005\">",
"     'Medical model'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    IPT is efficacious for several types of depressed patients, including those who are [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/9,12,13\">",
"     9,12,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pregnant",
"     </li>",
"     <li>",
"      Postpartum",
"     </li>",
"     <li>",
"      At risk for postpartum depression",
"     </li>",
"     <li>",
"      Mothers with a psychiatrically ill child",
"     </li>",
"     <li>",
"      At risk for recurrences of depression",
"     </li>",
"     <li>",
"      HIV-positive",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is also evidence that IPT is useful for primary care settings and in developing countries [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/9,12,13\">",
"     9,12,13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H91117124\">",
"     'Evidence of efficacy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91116976\">",
"    <span class=\"h1\">",
"     THEORETICAL FOUNDATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The theoretical roots of Interpersonal Psychotherapy (IPT) explain its conceptual approach and distinguish it from other psychotherapies [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91116983\">",
"    <span class=\"h2\">",
"     Interpersonal school of psychoanalysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;IPT is based upon the theoretical framework of the interpersonal school of psychoanalysis, which maintains that relationships are the most basic and important aspect of human experience, rather than drives [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. This school emphasized that interpersonal conflicts and social problems cause depression and other forms of psychopathology, as opposed to the psychoanalytic focus on intra-psychic conflict as the primary cause of depression [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. IPT was also shaped by the belief that psychotherapy for depression should address the patient&rsquo;s social and cultural experiences [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This framework is supported by research that suggests a reciprocal link between interpersonal relationships and depressive symptoms. One study found that confiding, supportive interpersonal relationships were protective against depression [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/5\">",
"     5",
"    </a>",
"    ], and other studies have found that relationship distress was associated with higher rates of major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/23\">",
"     23",
"    </a>",
"    ]. Conversely, studies have found that depression was associated with impaired communication and activity within relationships [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/4\">",
"     4",
"    </a>",
"    ], and higher rates of marital discord [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91116990\">",
"    <span class=\"h2\">",
"     Attachment theory",
"    </span>",
"    &nbsp;&mdash;&nbsp;IPT also draws upon attachment theory, which states that the relationship between a caregiver and infant is crucial to survival and remains essential throughout life [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/18,24\">",
"     18,24",
"    </a>",
"    ]. Attachment helps determine whether development is normal. A secure attachment early in life lays the foundation for psychological security and a capacity for healthy intimacy in adult relationships, whereas early disturbances in attachment contribute to the vulnerability to depression and other psychopathology. In addition, differences in early attachment experiences translate into different adult relationship styles. Adult attachment styles appear to moderate treatment outcomes with IPT. (See",
"    <a class=\"local\" href=\"#H91117280\">",
"     'Predictors of treatment response'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174665058\">",
"    <span class=\"h2\">",
"     Stress-diathesis model",
"    </span>",
"    &nbsp;&mdash;&nbsp;The stress-diathesis model is utilized in IPT. The model states that depression occurs when patients with a biological vulnerability (diathesis) to the illness experience adverse life events of sufficient severity to provoke the diathesis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/25\">",
"     25",
"    </a>",
"    ]. Patients are not responsible for causing their illness, but can help themselves by actively addressing the recent interpersonal problems that trigger the underlying biologic illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91116997\">",
"    <span class=\"h1\">",
"     GENERAL CONCEPTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interpersonal Psychotherapy (IPT) is a time-limited, structured, manual-guided treatment based upon the medical model [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/2,26\">",
"     2,26",
"    </a>",
"    ]. The therapy emphasizes current relationships and the connection between recent adverse life events and depression. The putative mechanism of action is that mood improves as the patient resolves interpersonal problems due to grief, role disputes, role transitions, and general interpersonal deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91117005\">",
"    <span class=\"h2\">",
"     Medical model",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with IPT occurs within the context of the medical model, which views depression as a clinical syndrome, distinct from the patient&rsquo;s personality [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/18\">",
"     18",
"    </a>",
"    ]. The clinician initially takes a psychiatric history, performs a mental status examination, and diagnoses a current episode of major depression according to DSM-IV-TR criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/28\">",
"     28",
"    </a>",
"    ]. The explanation of the diagnosis should liken depression to other medical illnesses (\"no different than asthma, diabetes or hypertension\"). In addition, the clinician should stress that [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient probably has an inherited, biologic vulnerability to depression",
"     </li>",
"     <li>",
"      It is not the patient&rsquo;s fault for developing depression (&ldquo;just like it is not someone's fault for developing asthma&rdquo;)",
"     </li>",
"     <li>",
"      Depression does not represent a character flaw",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91117012\">",
"    <span class=\"h2\">",
"     Link between life events and depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Throughout treatment, the clinician emphasizes the connection between psychosocial stressors and the patient's depression. Therapy focuses upon identifying the interpersonal antecedents of depressive episodes and examining the impact of both positive and negative life events on the patient&rsquo;s symptoms. The basic principle is that the depressive syndrome will improve as interpersonal problems resolve. In addition, the bi-directional nature of the relationship between interpersonal functioning and mood is highlighted. In an iterative process, improved mood allows patients to more effectively manage interpersonal stressors, which leads to further symptomatic relief.",
"   </p>",
"   <p>",
"    The clinician does not take the position that life events cause depression per se. Rather, the clinician acknowledges that mood symptoms can contribute to negative interpersonal interactions just as problematic interpersonal events contribute to mood destabilization. As these effects are co-occurring, it is impossible to assign causal roles. &nbsp;From a treatment standpoint, it is important to address both aspects of this dynamic",
"   </p>",
"   <p>",
"    IPT and psychodynamic psychotherapy both focus upon relationships and events, but differ in several ways. IPT assumes that recent life events are associated with onset and maintenance of the current depressive episode, and that addressing these \"here and now\" proximal events resolves the depressive episode more rapidly than addressing older \"there and then\" conflicts [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/3\">",
"     3",
"    </a>",
"    ]. Another difference is that IPT is not aimed at unconscious processes and does not focus upon the transference relationship between the clinician and the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28328?source=see_link\">",
"     \"Depression in adults: Psychodynamic psychotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91117026\">",
"    <span class=\"h2\">",
"     Interpersonal problem areas",
"    </span>",
"    &nbsp;&mdash;&nbsp;In IPT, there are four categories of interpersonal problems that are associated with the onset or maintenance of depression: grief (complicated bereavement), role dispute, role transition, and interpersonal deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/13,18\">",
"     13,18",
"    </a>",
"    ]. Therapy focuses upon the one or two most problematic areas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91117033\">",
"    <span class=\"h3\">",
"     Grief",
"    </span>",
"    &nbsp;&mdash;&nbsp;The death or disappearance of an important person that was not adequately resolved results in an abnormal grief reaction that is delayed or prolonged [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/18\">",
"     18",
"    </a>",
"    ]. The goals of treatment consist of helping the patient experience the normal grief process, which includes feeling pain, sadness, and other emotions; letting go of the deceased; and moving on with life by re-establishing social contacts and resuming activities [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Losses other than death, such as loss of physical health or the end of a relationship, are categorized as role transition. (See",
"    <a class=\"local\" href=\"#H91117047\">",
"     'Role transition'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91117040\">",
"    <span class=\"h3\">",
"     Role dispute",
"    </span>",
"    &nbsp;&mdash;&nbsp;A role dispute consists of a conflict with a significant other (spouse, partner, family member, close friend, or coworker) over different expectations about the relationship. Most often the dispute is with a spouse or romantic partner [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/18\">",
"     18",
"    </a>",
"    ]. The inability to negotiate a compromise leads to an unsatisfying relationship that in turn is associated with the onset or maintenance of the depression. Therapy focuses on helping the patient to understand the nature of the dispute and to develop skills for resolving the dispute.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91117047\">",
"    <span class=\"h3\">",
"     Role transition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may experience difficulty in coping with a major change in life circumstances. Role transitions occur in many domains, including interpersonal roles (eg, marriage, becoming a parent, or divorce), occupation (eg, graduation from school, leaving one job for another, or retirement), physical health (eg, diagnosis of a serious medical illness), living conditions (eg, moving), or socioeconomic status (eg, financial problems) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/30\">",
"     30",
"    </a>",
"    ]. The transition is conceptualized as moving from one social role to another social role. The goal of treatment is to establish a realistic view of both the previous role (which is usually idealized) and the new role (which is usually devalued), and then to develop better strategies to cope with the new role.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91117054\">",
"    <span class=\"h3\">",
"     Interpersonal deficits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interpersonal deficits are marked by pervasive problems starting and maintaining relationships; social isolation; and chronically impoverished, contentious, and unfulfilling relationships. Although many patients seeking IPT treatment have deficits in interpersonal functioning, the interpersonal deficits category is reserved for cases when there is no clear acute interpersonal event associated with the onset or maintenance of the depressive episode. Therapy aims to reduce social isolation by increasing new relationships. Patients with chronic impairment in social functioning, who lack the life events upon which IPT focuses, fare worse in treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91117124\">",
"    <span class=\"h1\">",
"     EVIDENCE OF EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Research studies indicate that Interpersonal Psychotherapy (IPT) effectively treats depressed adults.",
"   </p>",
"   <p>",
"    Psychotherapy trials, like pharmacotherapy trials, are methodologically variable. Some psychotherapy trials are rigorous and specify a priori hypotheses and analytic tests, use active psychotherapy comparators that control for the nonspecific aspects of psychotherapy, use standardized diagnostic criteria and outcome measures, carefully blind outcome ratings, develop manuals for the psychotherapies that are studied and measure adherence, and stratify patients on predetermined risk variables. Less meticulous studies use methods such as open-label designs, less rigorous comparators (eg, treatment as usual or waiting lists), or fail to adequately blind outcome ratings. Although it is commonly believed that blinding of patients in psychotherapy is less successful compared with pharmacotherapy trials, this has never been studied.",
"   </p>",
"   <p>",
"    Clinical trials with different control conditions have demonstrated the efficacy of IPT for acute and maintenance treatment of unipolar major depression in specialty mental health and primary care settings [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/9,12,13\">",
"     9,12,13",
"    </a>",
"    ]. In addition, a meta-analysis of 117 randomized psychotherapy trials found no evidence of publication bias for trials of IPT [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/32\">",
"     32",
"    </a>",
"    ]. Furthermore, IPT is efficacious for several subgroups of depressed patients, including women in the childbearing years and patients infected with the human immunodeficiency virus (HIV). (See",
"    <a class=\"local\" href=\"#H91120529\">",
"     'Indications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Meta-analyses of randomized trials have found that IPT works at least as well as other psychotherapies for treating acute depression [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/17\">",
"     17",
"    </a>",
"    ]. As an example, a meta-analysis of 53 randomized trials (2757 patients with mild to moderate depression) found a significant but clinically small effect favoring IPT compared with six other psychotherapies combined (cognitive-behavior therapy, supportive treatment, behavior activation treatment, psychodynamic psychotherapy, problem-solving therapy, and social skills training) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/33\">",
"     33",
"    </a>",
"    ]. A separate analysis of five trials that directly compared IPT with cognitive-behavioral therapy (CBT) found no significant difference in efficacy.",
"   </p>",
"   <p>",
"    A meta-analysis of 10 randomized trials (number of patients not specified) found a significant, but clinically small effect favoring pharmacotherapy over IPT for treatment of acute depression (after removal of one possible outlier) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The combination of IPT and an antidepressant medication appears to relieve depressive symptoms more than medication alone. A meta-analysis of eight randomized trials (685 patients with major depression or dysthymia) found a significant, but clinically small effect favoring combination treatment (10 to 24 sessions of IPT plus an antidepressant) over pharmacotherapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4202853\">",
"    <span class=\"h2\">",
"     Depressive syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;IPT effectively treats acute episodes of unipolar major depression. In addition, IPT delays and prevents recurrent episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/34-38\">",
"     34-38",
"    </a>",
"    ]. However, patients greater than 70 years of age and patients with dysthymic disorder fare better with an antidepressant than with IPT for acute and maintenance treatment of depression [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/38-41\">",
"     38-41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2291366\">",
"    <span class=\"h3\">",
"     Acute unipolar major depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of IPT for acute unipolar major depression is well established. A meta-analysis of 16 randomized trials (number of patients not specified) found a statistically significant effect favoring IPT over waiting list, usual care, or pill placebo, and the clinical effect was moderately large [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/17\">",
"     17",
"    </a>",
"    ]. Treatment of approximately three patients with IPT yielded a beneficial response in one additional patient that would not have occurred with the control condition (number needed to treat of three).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2291374\">",
"    <span class=\"h3\">",
"     Recurrent unipolar major depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major depression often recurs; for patients who have recovered from an episode of depression, IPT efficaciously delays and prevents recurrences of major depression. A meta-analysis of four randomized maintenance trials (number of patients not specified) found that recurrence was reduced in patients who received IPT plus pill placebo compared with pill placebo alone (OR 0.5, 95% CI 0.3-0.9) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/17\">",
"     17",
"    </a>",
"    ]. A second meta-analysis of four randomized maintenance trials (number of patients not specified) found that recurrence was reduced in patients who received IPT plus pharmacotherapy compared with pharmacotherapy alone (OR 0.4, 95% CI 0.2-0.7). However, the benefit of maintenance IPT may be less robust for patients aged 70 years and older [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Monthly sessions of maintenance IPT seem to be as effective as more frequently scheduled sessions for preventing recurrences in patients who have recovered from an episode of major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/42\">",
"     42",
"    </a>",
"    ]. A randomized trial enrolled 131 patients who had recovered from an episode of recurrent major depression (with IPT monotherapy or IPT plus a selective serotonin reuptake inhibitor), and assigned them to maintenance treatment with weekly, twice-monthly, or monthly sessions of IPT monotherapy. Time to recurrence did not differ significantly between the three groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2291390\">",
"    <span class=\"h3\">",
"     Dysthymic disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;IPT has been adapted for patients with dysthymic disorder, which is marked by dysphoria for at least two years and other symptoms including disturbed appetite, sleep, or energy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/43\">",
"     43",
"    </a>",
"    ]. In addition, patients typically describe impoverished interpersonal relationships in the context of hopelessness and low self-esteem. The central feature of IPT adapted for dysthymia is that patients learn to view their illness as a mood disorder (treatable state) rather than a core feature of their personality (immutable trait), and to develop new, healthy interpersonal relationships [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/8\">",
"     8",
"    </a>",
"    ]. The clinical manifestations and diagnosis of dysthymic disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations and diagnosis of depression\", section on 'Dysthymic disorder'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Two studies indicate that IPT is less efficacious than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    for treating symptoms of dysthymia, and that augmenting sertraline with IPT provides no added benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. However, IPT may help reduce costs of health care and social services, and reduce time lost from work. It is not known whether IPT is more effective than no treatment or a less intense treatment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial assigned 94 patients with dysthymic disorder to 16 weeks of treatment with IPT adapted for dysthymia (IPT-D), brief supportive therapy,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      , or sertraline plus IPT-D [",
"      <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/39\">",
"       39",
"      </a>",
"      ]. Response (&ge; 50 percent improvement in baseline depression rating scale scores) occurred in significantly fewer patients who received IPT-D alone or brief supportive therapy, compared with patients who received sertraline alone or sertraline plus IPT-D (35 and 31 versus 58 and 57 percent).",
"     </li>",
"     <li>",
"      A randomized trial assigned 707 primary care patients with dysthymic disorder to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      , IPT (not adapted specifically for dysthymia), or sertraline plus IPT [",
"      <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/40\">",
"       40",
"      </a>",
"      ]. Patients received sertraline for up to 2 years and up to 12 sessions of IPT over a 6 month period. Response (&ge; 40 percent improvement in baseline depression rating scale scores) at 6 months occurred in significantly fewer patients who received IPT alone compared with patients who received sertraline alone or sertraline plus IPT (47 versus 60 and 58 percent). IPT alone was also inferior at the two year assessment. However, total costs for health care services, social services, and lost wages over two years were significantly lower in patients who received IPT alone, compared with the other two treatments.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4203615\">",
"    <span class=\"h2\">",
"     Depressed patients with medical comorbidities",
"    </span>",
"    &nbsp;&mdash;&nbsp;IPT may be efficacious for some depressed patients with a comorbid nonpsychiatric medical illness. Depressed patients infected with the human immunodeficiency virus (HIV) benefitted from IPT, but depressed patients with coronary heart disease did not [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. In addition, patients with irritable bowel syndrome (depression status was not considered) responded to IPT, suggesting depressed patients with irritable bowel syndrome may also respond to IPT [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2291219\">",
"    <span class=\"h3\">",
"     Depression and HIV-seropositivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial showed that IPT is efficacious for depressed patients who are HIV positive [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/44\">",
"     44",
"    </a>",
"    ]. The therapy was modified to address concerns about physical illness, death, grief, and social stigma associated with HIV and the acquired immunodeficiency syndrome (AIDS).",
"    <br/>",
"    <br/>",
"    The trial assigned 101 depressed, HIV-positive patients to 16 weeks of treatment with IPT, cognitive-behavioral therapy (CBT), supportive therapy, or supportive therapy plus with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"     imipramine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/44\">",
"     44",
"    </a>",
"    ]. Most patients were not severely ill due to HIV infection. Baseline depression rating scale scores improved significantly more with either IPT or imipramine plus supportive therapy, compared with CBT or supportive therapy alone. The rate of remission of depressive symptoms with imipramine plus supportive therapy was 50 percent, IPT 46 percent, CBT 30 percent, and supportive therapy 21 percent. Ratings of physical functioning were also significantly better in patients treated with IPT or imipramine plus supportive therapy. The investigators speculated that IPT may be a better fit than CBT because the problems facing patients who are HIV-positive constitute &ldquo;real problems&rdquo; rather than cognitive distortions.",
"    <br/>",
"    <br/>",
"    Another trial randomly assigned 79 patients with major depression or dysthymia and an HIV-AIDS diagnosis to either 6 sessions of telephone-delivered IPT or usual care [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/47\">",
"     47",
"    </a>",
"    ]. Symptoms of depression decreased significantly more in patients who received IPT compared to usual care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2291250\">",
"    <span class=\"h3\">",
"     Depression and coronary heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial with 284 patients found that IPT was no better than clinical management (nonspecific support) for treatment of comorbid major depression and coronary heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88147643\">",
"    <span class=\"h2\">",
"     Depressed patients in different settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;IPT has been transported from specialty mental health clinics and demonstrated efficacy for treating depression in primary care settings and in developing countries [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/48-51\">",
"     48-51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2291261\">",
"    <span class=\"h3\">",
"     Primary care settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;A trial randomly assigned 276 primary care patients with unipolar major depression to 20 sessions of IPT,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    , or the primary care physician's usual treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/48\">",
"     48",
"    </a>",
"    ]. All treatments were administered over an 8 month period in the primary care clinic, and IPT was administered by mental health specialists. IPT and nortriptyline each led to significantly greater improvement of baseline depression rating scale scores, compared with usual care. In addition, recovery occurred in significantly more patients treated with IPT or nortriptyline, compared with usual care (46 and 48 versus 18 percent). Other studies have successfully used IPT in primary care settings [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2291279\">",
"    <span class=\"h3\">",
"     Developing countries",
"    </span>",
"    &nbsp;&mdash;&nbsp;IPT was adapted and successfully used within a group therapy format for treatment of major depression in rural Uganda, where an HIV epidemic has occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. IPT groups met for 16 weekly sessions, each lasting 90 minutes, and were single-sex in composition to facilitate disclosure and accommodate local attitudes and customs [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/49\">",
"     49",
"    </a>",
"    ]. The basic structure of IPT was retained but simplified so that groups could be led by non-clinicians. Investigators randomly assigned 30 villages (341 patients with self-identified depression) to group IPT plus usual care or usual care alone. Improvement of depressive symptoms and psychosocial functioning was significantly greater among patients treated with group IPT, and significantly fewer patients who received group IPT met criteria for major depression, compared with the control group (7 versus 55 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/50\">",
"     50",
"    </a>",
"    ]. The benefits of IPT persisted at six-month follow-up, such that the rate of major depression was significantly lower in the IPT group compared with the control group (12 versus 55 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88148850\">",
"    <span class=\"h2\">",
"     Depression in adolescent and older patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;IPT has demonstrated success in treating adolescent patients. However, the results with older patients are mixed. Bereavement-related major depression in older patients appears to be better treated with pharmacotherapy than with IPT [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/41\">",
"     41",
"    </a>",
"    ]. Maintenance treatment with IPT appears to prevent depressive recurrences in patients aged 60 to 69 years, but not in patients aged 70 years and older [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2291314\">",
"    <span class=\"h3\">",
"     Depressed adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;IPT has been successfully adapted for depressed adolescents (IPT-A) to address their specific interpersonal issues, including separation from parents, autonomy in relationship to parents, peer pressure, dyadic interpersonal relationships, death of a friend or a relative, and single-parent families [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/53\">",
"     53",
"    </a>",
"    ]. An overview of IPT-A, including evidence supporting its use, is discussed separately (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4328?source=see_link&amp;anchor=H14#H14\">",
"     \"Psychosocial treatment for adolescent depression\", section on 'Interpersonal psychotherapy for adolescents (IPT-A)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2291321\">",
"    <span class=\"h3\">",
"     Older patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of IPT appear to dissipate in patients aged 70 years and older, and appear to be maximally effective when combined with pharmacotherapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial enrolled 80 patients aged 50 years and older, with acute bereavement-related major depression, and assigned them one of four treatments, each lasting 16 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/41\">",
"       41",
"      </a>",
"      ]. The rate of remission with placebo plus IPT was 29 percent, placebo plus medication visits 45 percent,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"       nortriptyline",
"      </a>",
"      plus medication visits 56 percent, and IPT plus nortriptyline 69 percent.",
"     </li>",
"     <li>",
"      A randomized trial assigned 124 patients with unipolar major depression, who partially responded to six weeks of treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/56/25481?source=see_link\">",
"       escitalopram",
"      </a>",
"      , to augmentation with either IPT or depression care management (nonspecific psychoeducation and supportive treatment) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/54\">",
"       54",
"      </a>",
"      ]. Patients were aged 60 years and older. Remission rates for escitalopram with IPT and with depression care management were similar (58 versus 45 percent).",
"     </li>",
"     <li>",
"      Randomized trials found that patients aged 60 to 69 years benefited from IPT as maintenance treatment to prevent recurrence of major depression, but that patients aged 70 years and older did not [",
"      <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H4202853\">",
"       'Depressive syndromes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91117202\">",
"    <span class=\"h2\">",
"     Women in the childbearing years",
"    </span>",
"    &nbsp;&mdash;&nbsp;IPT is efficacious for several different populations of depressed women in their childbearing years, including women who are pregnant, postpartum, have had a miscarriage, or have a psychiatrically ill child [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/55-60\">",
"     55-60",
"    </a>",
"    ]. IPT also appears to prevent postpartum depression in women who are at risk for the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/61\">",
"     61",
"    </a>",
"    ]. However, it is not known whether IPT has greater utility in women compared with men [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pregnancy and parenthood involve role transitions. Treating depressed, pregnant or postpartum women with IPT usually involves examining the psychological changes associated with pregnancy, one&rsquo;s capabilities as a parent, and changes in relationships with one&rsquo;s spouse and other family members [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management of depression during pregnancy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=see_link\">",
"     \"Depression in pregnant women: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2291144\">",
"    <span class=\"h3\">",
"     Depression during pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial compared 16 sessions of IPT with a parenting education program, for treating unipolar major depression in 50 pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/58\">",
"     58",
"    </a>",
"    ]. IPT led to significantly more improvement of depression rating scale scores, and recovery occurred in significantly more women who received IPT compared with the control condition (60 versus 15 percent). In addition, improved mood translated into better mother&ndash;infant interactions at the first postpartum visit.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial compared IPT (nine sessions) with treatment as usual in 53, low-income pregnant depressed women (nearly all had major depression) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/59\">",
"       59",
"      </a>",
"      ]. Both treatment groups received case-management services. Before childbirth, response (&ge; 50 percent improvement of baseline depression rating scale scores) occurred in significantly more patients who received IPT compared with control patients (80 versus 25 percent). In addition, monthly maintenance sessions with IPT resulted in significantly greater rates of response at six months postpartum, compared with usual care (88 versus 25 percent).",
"     </li>",
"     <li>",
"      In two case series, pregnant adolescents (average mean age 15 and 17 years) with depression received 12 weekly sessions of IPT in a group format [",
"      <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/63\">",
"       63",
"      </a>",
"      ]. Depressive symptoms decreased by 40 and 50 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2291155\">",
"    <span class=\"h3\">",
"     Postpartum depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial compared 12 sessions of IPT with a waiting-list control condition, for treatment of 120 patients with postpartum unipolar major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/56\">",
"     56",
"    </a>",
"    ]. Onset of the depressive episode occurred after childbirth in the majority of patients. Improvement of depressive symptoms and psychosocial functioning was significantly greater with IPT, and recovery occurred in significantly more patients who received IPT compared with waiting list patients (32 versus 15 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2291165\">",
"    <span class=\"h3\">",
"     Depression following a miscarriage",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial compared IPT with treatment as usual in 19 women with subsyndromal depression following a miscarriage [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/60\">",
"     60",
"    </a>",
"    ]. IPT was modified for administration over the telephone by counselors who were not necessarily mental health clinicians, and sessions were fewer (1 to 6), shorter (30 minutes), and more highly scripted. Baseline depression rating scale scores decreased significantly more with IPT than usual care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2291176\">",
"    <span class=\"h3\">",
"     Patients at risk for postpartum depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial compared four, 60 minute sessions of group IPT with treatment as usual in 37 low-income women who had at least one risk factor for postpartum depression (previous episode of depression or postpartum depression, mild to moderate depressive symptoms not meeting criteria for major depression, poor social supports, or a life stressor within the prior six months) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/61\">",
"     61",
"    </a>",
"    ]. Within three months of giving birth, postpartum depression occurred in significantly fewer women treated with IPT (0 versus 33 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2291186\">",
"    <span class=\"h2\">",
"     Mothers of children with psychiatric disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;For depressed mothers who have a psychiatrically ill child, IPT for the mother appears to relieve depressive symptoms in both the mother and child. A randomized trial compared IPT (nine sessions) with usual care for treatment of unipolar major depression in 47 mothers with a child receiving psychiatric treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/55\">",
"     55",
"    </a>",
"    ]. IPT was modified to include some behavioral strategies and motivational interviewing. Maternal baseline depression and psychosocial functioning rating scale scores improved significantly more with IPT than usual care, and treatment gains persisted at the nine-month follow-up. In addition, child depression and functioning scores were significantly better in the offspring of mothers assigned to IPT, compared with the offspring of mothers assigned to treatment as usual.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2291197\">",
"    <span class=\"h3\">",
"     Mothers of children age 0 to 3 years",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial assigned 80 immigrant Latina mothers with limited English language skills to 11 sessions of nurse-delivered, in-home, IPT (plus 5 follow-up booster sessions) or to usual care [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/64\">",
"     64",
"    </a>",
"    ]. Depressive symptoms decreased significantly more in patients who received IPT compared with usual care. In addition, the child&rsquo;s aggression decreased significantly more in mothers who received IPT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4205342\">",
"    <span class=\"h2\">",
"     Sexually abused women and incarcerated women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Open-label pilot studies suggest IPT may be useful for depressed women with a history of childhood sexual abuse and for incarcerated women who are depressed and have a substance use disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91117280\">",
"    <span class=\"h1\">",
"     PREDICTORS OF TREATMENT RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Response to Interpersonal Psychotherapy (IPT) is associated with fewer comorbid anxiety symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/67,68\">",
"     67,68",
"    </a>",
"    ], less social impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/31\">",
"     31",
"    </a>",
"    ], single or separated marital status [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/69\">",
"     69",
"    </a>",
"    ], the presence of obsessive-compulsive personality traits [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/69\">",
"     69",
"    </a>",
"    ], lower levels of attachment avoidance and attachment anxiety [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/70-72\">",
"     70-72",
"    </a>",
"    ], and normal pretreatment EEG sleep profiles [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/73\">",
"     73",
"    </a>",
"    ]. In addition, IPT has been successfully used in more severely depressed patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2290999\">",
"    <span class=\"h2\">",
"     Depression severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Higher baseline severity of depression is generally a non-specific predictor of worse outcomes for depressed patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/74\">",
"     74",
"    </a>",
"    ]. It is also a moderator of treatment response such that lower severity is associated with better response to either placebo or less intense treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/75\">",
"     75",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    It is not clear whether IPT is superior to CBT for more severely depressed patients. In one randomized trial, high baseline depression severity predicted superior response to either IPT or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"     imipramine",
"    </a>",
"    , but not CBT, compared with placebo plus clinical management [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/31,35\">",
"     31,35",
"    </a>",
"    ]. In a different randomized trial, CBT was more effective than IPT for severe depression [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2291017\">",
"    <span class=\"h2\">",
"     Anxiety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anxiety occurs often in depressed patients, and comorbid anxiety consistently predicts worse outcomes for depressed patients treated with IPT [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. In 134 women treated for recurrent major depression with IPT, the probability of remission was two-fold less in patients with higher levels of baseline somatic anxiety (eg, dry mouth, indigestion, belching, palpitations, headache, sighing, and sweating) (OR 2.0, 95% CI 1.1-3.6) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/67\">",
"     67",
"    </a>",
"    ]. Another study of 61 women with recurrent depression found that remission occurred in significantly fewer patients with a lifetime history of clinically meaningful anxiety symptoms compared to patients with no such history (43 versus 68 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/68\">",
"     68",
"    </a>",
"    ]. In response to these observations, a modified form of IPT for patients with depression and comorbid anxiety symptoms has been developed, which includes some CBT techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/77\">",
"     77",
"    </a>",
"    ]. This treatment needs to be evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2291035\">",
"    <span class=\"h2\">",
"     Psychosocial functioning and personality",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a randomized trial, less social impairment predicted superior response to IPT [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/31\">",
"     31",
"    </a>",
"    ]. Although it might be expected that poor interpersonal functioning in a depressed patient would be an indication to prescribe IPT, it seems that one must have a moderately intact level of interpersonal functioning in order for IPT to take hold. In other words, the clinician must have &ldquo;something to work with.&rdquo;",
"    <br/>",
"    <br/>",
"    A randomized trial assigned 177 patients with unipolar major depression to 16 weeks of IPT or CBT [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/78\">",
"     78",
"    </a>",
"    ]. Comorbid personality disorder adversely affected outcome with IPT but not CBT. A different randomized trial found that IPT was more effective than CBT for depressed patients with obsessive-compulsive personality traits, whereas CBT was more effective than IPT for patients with avoidant personality traits [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2291050\">",
"    <span class=\"h2\">",
"     Attachment style",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two types or dimensions of adult attachment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/70\">",
"     70",
"    </a>",
"    ]. Attachment anxiety refers to levels of anxiety about rejection by others. Attachment avoidance refers to levels of discomfort with closeness and intimacy.",
"   </p>",
"   <p>",
"    Response to treatment of depression with IPT is better in patients with lower levels of attachment avoidance and attachment anxiety [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]. A randomized trial compared IPT with CBT (16 to 20 weekly sessions of either psychotherapy) in 56 patients with major depression, and found that patients with greater levels of attachment avoidance were significantly less likely to remit with IPT [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/70\">",
"     70",
"    </a>",
"    ]. A second study found that among depressed patients who remitted with ITP, higher levels attachment anxiety and attachment avoidance were associated with a significantly longer time to clinical stabilization [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/71\">",
"     71",
"    </a>",
"    ]. A case series of 145 depressed patients treated with IPT found that there was significantly less attachment anxiety and attachment avoidance among patients who remitted, compared with patients who did not remit [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2291061\">",
"    <span class=\"h2\">",
"     Sleep EEG profiles",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 91 patients treated for major depression with IPT, remission occurred in significantly more patients with normal pretreatment EEG sleep profiles compared with abnormal pretreatment EEG sleep profiles (58 versus 37 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/16/17674/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91117329\">",
"    <span class=\"h1\">",
"     OTHER RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional resources that are available to learn more about using IPT include treatment manuals and a professional organization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/20/4425?source=see_link&amp;anchor=H1394899#H1394899\">",
"     \"Interpersonal Psychotherapy (IPT) for depressed adults: Specific interventions and techniques\", section on 'Other resources'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91117336\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Interpersonal Psychotherapy (IPT) is indicated for depressed patients. Monotherapy with IPT is often used to treat mild to moderate depression. Patients with moderate to severe depression, especially moderate to severe suicidal ideation or moderate to severe neurovegetative symptoms (decreased sleep, appetite, energy, and libido), generally require pharmacotherapy in addition to IPT. Combining IPT with pharmacotherapy is readily accomplished because IPT is based upon the medical model. (See",
"      <a class=\"local\" href=\"#H91120529\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The theoretical foundation of IPT includes the principle that relationships are the most important aspect of human experience. In addition, IPT draws upon the theory that the relationship between a caregiver and infant is crucial to survival and helps determine whether development is normal. IPT also applies a model which states that depression occurs when patients with a biological vulnerability to the illness experience adverse life events of sufficient severity. (See",
"      <a class=\"local\" href=\"#H91116976\">",
"       'Theoretical foundation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IPT is a time-limited, structured, manual-guided treatment based upon the medical model. The therapy emphasizes current relationships and the connection between recent adverse life events and depression. The putative mechanism of action is that mood improves as the patient resolves interpersonal problems due to grief, role disputes, role transitions, and interpersonal deficits. (See",
"      <a class=\"local\" href=\"#H91116997\">",
"       'General concepts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IPT works at least as well as other psychotherapies. IPT also delays and prevents recurrent episodes in patients less than 70 years old. However, older patients and patients with dysthymic disorder fare better with an antidepressant than with IPT. (See",
"      <a class=\"local\" href=\"#H91117124\">",
"       'Evidence of efficacy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4202853\">",
"       'Depressive syndromes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IPT may be efficacious for some depressed patients with a comorbid nonpsychiatric medical illness. Depressed patients infected with the human immunodeficiency virus (HIV) benefitted from IPT, but depressed patients with coronary heart disease did not. (See",
"      <a class=\"local\" href=\"#H4203615\">",
"       'Depressed patients with medical comorbidities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IPT has been transported from specialty mental health clinics and demonstrated efficacy for treating depression in primary care settings and in developing countries (See",
"      <a class=\"local\" href=\"#H88147643\">",
"       'Depressed patients in different settings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IPT has demonstrated success in treating adolescent patients. However, the results with older patients are mixed. Acute episodes of bereavement-related major depression in older patients appear to be better treated with pharmacotherapy than with IPT. Maintenance treatment with IPT appears to prevent depressive recurrences in patients aged 60 to 69 years, but not in patients aged 70 years and older. (See",
"      <a class=\"local\" href=\"#H88148850\">",
"       'Depression in adolescent and older patients'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      IPT is efficacious for several different populations of depressed women in their childbearing years, including women who are pregnant, postpartum, have had a miscarriage, or have a psychiatrically ill child. IPT also appears to prevent postpartum depression in women who are at risk for the disorder. (See",
"      <a class=\"local\" href=\"#H91117202\">",
"       'Women in the childbearing years'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Response to IPT is associated with fewer comorbid anxiety symptoms, less social impairment, single or separated marital status, the presence of obsessive-compulsive personality traits, lower levels of attachment avoidance and attachment anxiety, and normal pretreatment EEG sleep profiles. In addition, IPT has been successfully used in more severely depressed patients. (See",
"      <a class=\"local\" href=\"#H91117280\">",
"       'Predictors of treatment response'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Klerman, GL, Weissman, MM, Rounsaville, BJ, Chevron, ES. Interpersonal Psychotherapy of Depression, Basic Books, New York 1984.",
"    </li>",
"    <li>",
"     Weissman, MM, Markowitz, JC, Klerman, GL. Comprehensive Guide to Interpersonal Psychotherapy, Basic Books, New York 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/3\">",
"      Brown GW, Harris TO, Peto J. Life events and psychiatric disorders. 2. Nature of causal link. Psychol Med 1973; 3:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/4\">",
"      Coyne JC. Depression and the response of others. J Abnorm Psychol 1976; 85:186.",
"     </a>",
"    </li>",
"    <li>",
"     Brown, GW, Harris, T. Social origins of depression: A study of psychiatric disorders in women, Free Press, New York 1978.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/6\">",
"      Henderson S, Byrne G, Duncan-Jones P, et al. Social relationships, adversity and neurosis: a study of associations in a general population sample. Br J Psychiatry 1980; 136:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/7\">",
"      Weissman MM, Klerman GL, Paykel ES, et al. Treatment effects on the social adjustment of depressed patients. Arch Gen Psychiatry 1974; 30:771.",
"     </a>",
"    </li>",
"    <li>",
"     Markowitz, JC, Weissman, MM. Applications of individual interpersonal psychotherapy to specific disorders: Efficacy and indications. In: Textbook of Psychotherapeutic Treatments, Gabbard, GO (Eds), American Psychiatric Publishing, Inc, Washington, DC 2009. p.339.",
"    </li>",
"    <li>",
"     Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition  www.psych.org/guidelines/mdd2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/10\">",
"      Brody AL, Saxena S, Stoessel P, et al. Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings. Arch Gen Psychiatry 2001; 58:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/11\">",
"      Martin SD, Martin E, Rai SS, et al. Brain blood flow changes in depressed patients treated with interpersonal psychotherapy or venlafaxine hydrochloride: preliminary findings. Arch Gen Psychiatry 2001; 58:641.",
"     </a>",
"    </li>",
"    <li>",
"     Depression: the treatment and management of depression in adults (update). www.NICE.org.UK/CG90 (Accessed on October 12, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/13\">",
"      American Psychiatric Association. Practice Guideline for the treatment of patients with major depressive disorder, third edition. Am J Psychiatry 2010; 167:1.",
"     </a>",
"    </li>",
"    <li>",
"     Markowitz, JC. Interpersonal psychotherapy. In: The American Psychiatric Publishing Textbook of Psychiatry, Fifth Edition, Hales, RE, Yudofsky, SC, Gabbard, GO (Eds), American Psychiatric Publishing, Washington, DC 2008. p.1191.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/15\">",
"      Davidson JR. Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry 2010; 71 Suppl E1:e04.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/16\">",
"      Cuijpers P, Dekker J, Hollon SD, Andersson G. Adding psychotherapy to pharmacotherapy in the treatment of depressive disorders in adults: a meta-analysis. J Clin Psychiatry 2009; 70:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/17\">",
"      Cuijpers P, Geraedts AS, van Oppen P, et al. Interpersonal psychotherapy for depression: a meta-analysis. Am J Psychiatry 2011; 168:581.",
"     </a>",
"    </li>",
"    <li>",
"     Lipsitz, JD. Theory of interpersonal psychotherapy. In: Textbook of Psychotherapeutic Treatments, Gabbard, GO (Eds), American Psychiatric Publishing, Inc, Washington, DC 2009. p.289.",
"    </li>",
"    <li>",
"     Sullivan, HS. The Interpersonal Theory of Psychiatry, Norton, New York 1953.",
"    </li>",
"    <li>",
"     Meyer, A. Psychobiology: A Science of Man, Thomas, CC (Eds), Springfield, IL 1957.",
"    </li>",
"    <li>",
"     Fromm-Reichmann, F. Principles of Intensive Psychotherapy, University of Chicago Press, Chicago 1960.",
"    </li>",
"    <li>",
"     Frank, JD. Persuasion and Healing: A Comparative Study of Psychotherapy, Johns Hopkins University Press, Baltimore, MD 1973.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/23\">",
"      Weissman MM. Advances in psychiatric epidemiology: rates and risks for major depression. Am J Public Health 1987; 77:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/24\">",
"      Bowlby J. The making and breaking of affectional bonds. II. Some principles of psychotherapy. The fiftieth Maudsley Lecture. Br J Psychiatry 1977; 130:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/25\">",
"      Monroe SM, Simons AD. Diathesis-stress theories in the context of life stress research: implications for the depressive disorders. Psychol Bull 1991; 110:406.",
"     </a>",
"    </li>",
"    <li>",
"     Weissman, MM, Markowitz, JC, Klerman, GL. Clinician's Quick Guide to Interpersonal Psychotherapy, Oxford University Press, New York 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/27\">",
"      Markowitz JC, Bleiberg KL, Christos P, Levitan E. Solving interpersonal problems correlates with symptom improvement in interpersonal psychotherapy: preliminary findings. J Nerv Ment Dis 2006; 194:15.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/29\">",
"      Kendler KS, Gatz M, Gardner CO, Pedersen NL. A Swedish national twin study of lifetime major depression. Am J Psychiatry 2006; 163:109.",
"     </a>",
"    </li>",
"    <li>",
"     Swartz, HA, Markowitz, JC. Techniques of interpersonal therapy. In: Textbook of Psychotheraputic Treatment, Gabbard, GO (Eds), American Psychiatric Publishing, Inc, Washington, DC 2009. p.309.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/31\">",
"      Sotsky SM, Glass DR, Shea MT, et al. Patient predictors of response to psychotherapy and pharmacotherapy: findings in the NIMH Treatment of Depression Collaborative Research Program. Am J Psychiatry 1991; 148:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/32\">",
"      Cuijpers P, Smit F, Bohlmeijer E, et al. Efficacy of cognitive-behavioural therapy and other psychological treatments for adult depression: meta-analytic study of publication bias. Br J Psychiatry 2010; 196:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/33\">",
"      Cuijpers P, van Straten A, Andersson G, van Oppen P. Psychotherapy for depression in adults: a meta-analysis of comparative outcome studies. J Consult Clin Psychol 2008; 76:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/34\">",
"      Frank E, Kupfer DJ, Perel JM, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990; 47:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/35\">",
"      Elkin I, Shea MT, Watkins JT, et al. National Institute of Mental Health Treatment of Depression Collaborative Research Program. General effectiveness of treatments. Arch Gen Psychiatry 1989; 46:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/36\">",
"      DiMascio A, Weissman MM, Prusoff BA, et al. Differential symptom reduction by drugs and psychotherapy in acute depression. Arch Gen Psychiatry 1979; 36:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/37\">",
"      Reynolds CF 3rd, Frank E, Perel JM, et al. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years. JAMA 1999; 281:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/38\">",
"      Reynolds CF 3rd, Dew MA, Pollock BG, et al. Maintenance treatment of major depression in old age. N Engl J Med 2006; 354:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/39\">",
"      Markowitz JC, Kocsis JH, Bleiberg KL, et al. A comparative trial of psychotherapy and pharmacotherapy for \"pure\" dysthymic patients. J Affect Disord 2005; 89:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/40\">",
"      Browne G, Steiner M, Roberts J, et al. Sertraline and/or interpersonal psychotherapy for patients with dysthymic disorder in primary care: 6-month comparison with longitudinal 2-year follow-up of effectiveness and costs. J Affect Disord 2002; 68:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/41\">",
"      Reynolds CF 3rd, Miller MD, Pasternak RE, et al. Treatment of bereavement-related major depressive episodes in later life: a controlled study of acute and continuation treatment with nortriptyline and interpersonal psychotherapy. Am J Psychiatry 1999; 156:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/42\">",
"      Frank E, Kupfer DJ, Buysse DJ, et al. Randomized trial of weekly, twice-monthly, and monthly interpersonal psychotherapy as maintenance treatment for women with recurrent depression. Am J Psychiatry 2007; 164:761.",
"     </a>",
"    </li>",
"    <li>",
"     Markowitz, JC. Interpersonal psychotherapy for dysthymic disorder, American Psychiatric Press, Inc., Washington, DC 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/44\">",
"      Markowitz JC, Kocsis JH, Fishman B, et al. Treatment of depressive symptoms in human immunodeficiency virus-positive patients. Arch Gen Psychiatry 1998; 55:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/45\">",
"      Lesp&eacute;rance F, Frasure-Smith N, Koszycki D, et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA 2007; 297:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/46\">",
"      Zijdenbos IL, de Wit NJ, van der Heijden GJ, et al. Psychological treatments for the management of irritable bowel syndrome. Cochrane Database Syst Rev 2009; :CD006442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/47\">",
"      Ransom D, Heckman TG, Anderson T, et al. Telephone-delivered, interpersonal psychotherapy for HIV-infected rural persons with depression: a pilot trial. Psychiatr Serv 2008; 59:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/48\">",
"      Schulberg HC, Block MR, Madonia MJ, et al. Treating major depression in primary care practice. Eight-month clinical outcomes. Arch Gen Psychiatry 1996; 53:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/49\">",
"      Verdeli H, Clougherty K, Bolton P, et al. Adapting group interpersonal psychotherapy for a developing country: experience in rural Uganda. World Psychiatry 2003; 2:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/50\">",
"      Bolton P, Bass J, Neugebauer R, et al. Group interpersonal psychotherapy for depression in rural Uganda: a randomized controlled trial. JAMA 2003; 289:3117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/51\">",
"      Bass J, Neugebauer R, Clougherty KF, et al. Group interpersonal psychotherapy for depression in rural Uganda: 6-month outcomes: randomised controlled trial. Br J Psychiatry 2006; 188:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/52\">",
"      Alexopoulos GS, Reynolds CF 3rd, Bruce ML, et al. Reducing suicidal ideation and depression in older primary care patients: 24-month outcomes of the PROSPECT study. Am J Psychiatry 2009; 166:882.",
"     </a>",
"    </li>",
"    <li>",
"     Mufson, L, Moreau, D, Weissman, MM, Klerman, GL. Interpersonal Psychotherapy for Depressed Adolescents, Guilford Press, New York 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/54\">",
"      Reynolds CF 3rd, Dew MA, Martire LM, et al. Treating depression to remission in older adults: a controlled evaluation of combined escitalopram with interpersonal psychotherapy versus escitalopram with depression care management. Int J Geriatr Psychiatry 2010; 25:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/55\">",
"      Swartz HA, Frank E, Zuckoff A, et al. Brief interpersonal psychotherapy for depressed mothers whose children are receiving psychiatric treatment. Am J Psychiatry 2008; 165:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/56\">",
"      O'Hara MW, Stuart S, Gorman LL, Wenzel A. Efficacy of interpersonal psychotherapy for postpartum depression. Arch Gen Psychiatry 2000; 57:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/57\">",
"      Spinelli MG. Interpersonal psychotherapy for depressed antepartum women: a pilot study. Am J Psychiatry 1997; 154:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/58\">",
"      Spinelli MG, Endicott J. Controlled clinical trial of interpersonal psychotherapy versus parenting education program for depressed pregnant women. Am J Psychiatry 2003; 160:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/59\">",
"      Grote NK, Swartz HA, Geibel SL, et al. A randomized controlled trial of culturally relevant, brief interpersonal psychotherapy for perinatal depression. Psychiatr Serv 2009; 60:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/60\">",
"      Neugebauer R, Kline J, Markowitz JC, et al. Pilot randomized controlled trial of interpersonal counseling for subsyndromal depression following miscarriage. J Clin Psychiatry 2006; 67:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/61\">",
"      Zlotnick C, Johnson SL, Miller IW, et al. Postpartum depression in women receiving public assistance: pilot study of an interpersonal-therapy-oriented group intervention. Am J Psychiatry 2001; 158:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/62\">",
"      Zlotnick C, Elkin I, Shea MT. Does the gender of a patient or the gender of a therapist affect the treatment of patients with major depression? J Consult Clin Psychol 1998; 66:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/63\">",
"      Miller L, Gur M, Shanok A, Weissman M. Interpersonal psychotherapy with pregnant adolescents: two pilot studies. J Child Psychol Psychiatry 2008; 49:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/64\">",
"      Beeber LS, Holditch-Davis D, Perreira K, et al. Short-term in-home intervention reduces depressive symptoms in Early Head Start Latina mothers of infants and toddlers. Res Nurs Health 2010; 33:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/65\">",
"      Johnson JE, Zlotnick C. A pilot study of group interpersonal psychotherapy for depression in substance-abusing female prisoners. J Subst Abuse Treat 2008; 34:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/66\">",
"      Talbot NL, Conwell Y, O'Hara MW, et al. Interpersonal psychotherapy for depressed women with sexual abuse histories: a pilot study in a community mental health center. J Nerv Ment Dis 2005; 193:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/67\">",
"      Feske U, Frank E, Kupfer DJ, et al. Anxiety as a predictor of response to interpersonal psychotherapy for recurrent major depression: an exploratory investigation. Depress Anxiety 1998; 8:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/68\">",
"      Frank E, Shear MK, Rucci P, et al. Influence of panic-agoraphobic spectrum symptoms on treatment response in patients with recurrent major depression. Am J Psychiatry 2000; 157:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/69\">",
"      Barber JP, Muenz LR. The role of avoidance and obsessiveness in matching patients to cognitive and interpersonal psychotherapy: empirical findings from the treatment for depression collaborative research program. J Consult Clin Psychol 1996; 64:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/70\">",
"      McBride C, Atkinson L, Quilty LC, Bagby RM. Attachment as moderator of treatment outcome in major depression: a randomized control trial of interpersonal psychotherapy versus cognitive behavior therapy. J Consult Clin Psychol 2006; 74:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/71\">",
"      Cyranowski, JM, Bookwala, J, Feske, U, et, al. Adult attachment profiles, interpersonal difficulties, and response to interpersonal psychotherapy in women with recurrent major depression. J Soc Clin Psychol 2002; 21:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/72\">",
"      Ravitz, P, Maunder, R, McBride, C. Attachment, contemporary interpersonal theory and IPT: An integration of theoretical, clinical, and empirical perspectives. J Contemp Psychother 2008; 38:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/73\">",
"      Thase ME, Buysse DJ, Frank E, et al. Which depressed patients will respond to interpersonal psychotherapy? The role of abnormal EEG sleep profiles. Am J Psychiatry 1997; 154:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/74\">",
"      Hollon SD, Shelton RC, Wisniewski S, et al. Presenting characteristics of depressed outpatients as a function of recurrence: preliminary findings from the STAR*D clinical trial. J Psychiatr Res 2006; 40:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/75\">",
"      Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010; 303:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/76\">",
"      Luty SE, Carter JD, McKenzie JM, et al. Randomised controlled trial of interpersonal psychotherapy and cognitive-behavioural therapy for depression. Br J Psychiatry 2007; 190:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/77\">",
"      Cyranowski JM, Frank E, Shear MK, et al. Interpersonal psychotherapy for depression with panic spectrum symptoms: a pilot study. Depress Anxiety 2005; 21:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/16/17674/abstract/78\">",
"      Joyce PR, McKenzie JM, Carter JD, et al. Temperament, character and personality disorders as predictors of response to interpersonal psychotherapy and cognitive-behavioural therapy for depression. Br J Psychiatry 2007; 190:503.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15675 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-7DB0BEB7E6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_16_17674=[""].join("\n");
var outline_f17_16_17674=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H91117336\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91116969\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91120529\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91116976\">",
"      THEORETICAL FOUNDATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H91116983\">",
"      Interpersonal school of psychoanalysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H91116990\">",
"      Attachment theory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H174665058\">",
"      Stress-diathesis model",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91116997\">",
"      GENERAL CONCEPTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H91117005\">",
"      Medical model",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H91117012\">",
"      Link between life events and depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H91117026\">",
"      Interpersonal problem areas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H91117033\">",
"      - Grief",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H91117040\">",
"      - Role dispute",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H91117047\">",
"      - Role transition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H91117054\">",
"      - Interpersonal deficits",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91117124\">",
"      EVIDENCE OF EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4202853\">",
"      Depressive syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2291366\">",
"      - Acute unipolar major depression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2291374\">",
"      - Recurrent unipolar major depression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2291390\">",
"      - Dysthymic disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4203615\">",
"      Depressed patients with medical comorbidities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2291219\">",
"      - Depression and HIV-seropositivity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2291250\">",
"      - Depression and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88147643\">",
"      Depressed patients in different settings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2291261\">",
"      - Primary care settings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2291279\">",
"      - Developing countries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88148850\">",
"      Depression in adolescent and older patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2291314\">",
"      - Depressed adolescents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2291321\">",
"      - Older patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H91117202\">",
"      Women in the childbearing years",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2291144\">",
"      - Depression during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2291155\">",
"      - Postpartum depression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2291165\">",
"      - Depression following a miscarriage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2291176\">",
"      - Patients at risk for postpartum depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2291186\">",
"      Mothers of children with psychiatric disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2291197\">",
"      - Mothers of children age 0 to 3 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4205342\">",
"      Sexually abused women and incarcerated women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91117280\">",
"      PREDICTORS OF TREATMENT RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2290999\">",
"      Depression severity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2291017\">",
"      Anxiety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2291035\">",
"      Psychosocial functioning and personality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2291050\">",
"      Attachment style",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2291061\">",
"      Sleep EEG profiles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91117329\">",
"      OTHER RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91117336\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28328?source=related_link\">",
"      Depression in adults: Psychodynamic psychotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=related_link\">",
"      Depression in pregnant women: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/20/4425?source=related_link\">",
"      Interpersonal Psychotherapy (IPT) for depressed adults: Specific interventions and techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4328?source=related_link\">",
"      Psychosocial treatment for adolescent depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=related_link\">",
"      Treatment of resistant depression in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_16_17675="Screening SUDs";
var content_f17_16_17675=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F51180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F51180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Screening for alcohol and drug use: The CAGE-AID questionnaire",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Item",
"      </td>",
"      <td class=\"subtitle1\">",
"       Text",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1.",
"      </td>",
"      <td>",
"       Have you ever felt you ought to cut down on your drinking or drug use?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2.",
"      </td>",
"      <td>",
"       Have people annoyed you by criticizing your drinking or drug use?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3.",
"      </td>",
"      <td>",
"       Have you ever felt bad or guilty about your drinking or drug use?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4.",
"      </td>",
"      <td>",
"       Have your ever had a drink or used drugs first thing in the morning to steady your nerves or get rid of a hangover?",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    NOTE: The CAGE-AID is a modification of the CAGE questionnaire, adapted to include drugs in addition to alcohol use. Use of the CAGE-AID should be preceded by the following instruction: \"When thinking about drug use, include illegal drug use and the use of prescription drugs other than as prescribed.\"",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Brown, RL, Leonard, T, Saunders, LA, Papasouliotis, O. The prevalence and detection of substance use disorder among inpatients ages 18 to 49: An opportunity for prevention. Preventive Medicine 1998; 27:101. Illustration used with permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_16_17675=[""].join("\n");
var outline_f17_16_17675=null;
var title_f17_16_17676="Nutritional comparison of milk to alternative sources";
var content_f17_16_17676=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F74819&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F74819&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Nutritional comparison of cow's milk to alternative sources",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Milk alternatives, per 8 ounce",
"      </td>",
"      <td class=\"subtitle1\">",
"       Kcal",
"      </td>",
"      <td class=\"subtitle1\">",
"       Protein, grams",
"      </td>",
"      <td class=\"subtitle1\">",
"       Fat, grams",
"      </td>",
"      <td class=\"subtitle1\">",
"       Calcium, mg",
"      </td>",
"      <td class=\"subtitle1\">",
"       Vitamin D, units",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cow's milk, whole/2 percent/skim",
"      </td>",
"      <td>",
"       150/130/85",
"      </td>",
"      <td>",
"       8",
"      </td>",
"      <td>",
"       8/5/&lt;1",
"      </td>",
"      <td>",
"       300",
"      </td>",
"      <td>",
"       100",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Enriched soy milk",
"      </td>",
"      <td>",
"       100",
"      </td>",
"      <td>",
"       7",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       350",
"      </td>",
"      <td>",
"       100",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Enriched rice milk",
"      </td>",
"      <td>",
"       120",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       2.5",
"      </td>",
"      <td>",
"       300",
"      </td>",
"      <td>",
"       100",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Enriched oat milk",
"      </td>",
"      <td>",
"       120",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       300",
"      </td>",
"      <td>",
"       100",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Enriched almond milk",
"      </td>",
"      <td>",
"       50",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       2.5",
"      </td>",
"      <td>",
"       300",
"      </td>",
"      <td>",
"       100",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Enriched potato milk",
"      </td>",
"      <td>",
"       70",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       300",
"      </td>",
"      <td>",
"       NA",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Infant formula (Alimentum)",
"      </td>",
"      <td>",
"       160",
"      </td>",
"      <td>",
"       4.4",
"      </td>",
"      <td>",
"       8.9",
"      </td>",
"      <td>",
"       168",
"      </td>",
"      <td>",
"       72",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Toddler formula (Neocate Junior)",
"      </td>",
"      <td>",
"       240",
"      </td>",
"      <td>",
"       8",
"      </td>",
"      <td>",
"       12",
"      </td>",
"      <td>",
"       271",
"      </td>",
"      <td>",
"       104",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Juice - 10 percent (30 percent) calcium fortified",
"      </td>",
"      <td>",
"       120",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       100 (300)",
"      </td>",
"      <td>",
"       Varies",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_16_17676=[""].join("\n");
var outline_f17_16_17676=null;
var title_f17_16_17677="Monoexponential DUN versus time";
var content_f17_16_17677=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F62830&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F62830&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 513px\">",
"   <div class=\"ttl\">",
"    Graph showing the mean dialysate urea nitrogen time concentration profile during sustained low efficiency dialysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 493px; height: 333px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Monoexponential fitted for DUN time-concentration profile. Mean dialysate urea nitrogen (DUN) time-concentration profile during sustained low efficiency dialysis (SLED) in nine patients investigated at UAMS. A single exponential curve fits these data (r=0.99). Divide the BUN by 2.8 to convert to mmol/L.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_16_17677=[""].join("\n");
var outline_f17_16_17677=null;
var title_f17_16_17678="Knee splint";
var content_f17_16_17678=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Knee splint",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 344px; height: 188px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With the knee placed in full extension, six-inch plaster rolls extend from the buttocks posteriorly to three inches above the malleoli.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_16_17678=[""].join("\n");
var outline_f17_16_17678=null;
var title_f17_16_17679="Injection for plantar fasciitis";
var content_f17_16_17679=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F61694&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F61694&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Injection technique for plantar fasciitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 414px; height: 233px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intralesional injections are performed in the areas of point tenderness noted on physical examination. Injections should begin distally, and move toward the heel if multiple sites are affected. Prepare the area with soap and alcohol. A one inch No. 23 or No. 25 needle is inserted 1/4 to 1/2 inch deep into the plantar fascia, injecting a mixture of corticosteroid and local anesthetic (1 mL of 1 percent lidocaine hydrochloride, and 20 to 40 mg methylprednisolone or equivalent; no more than 40 mg methylprednisolone or equivalent for each foot). The mixture will flocculate within the syringe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sheon, RP, Moskowitz, RW, Goldberg, VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_16_17679=[""].join("\n");
var outline_f17_16_17679=null;
